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I.1 GENERAL INTRODUCTION 
In 2002, the Food and Drug Administration (FDA) announced the “Pharmaceutical Current Good 
Manufacturing Practices (cGMP) for the 21st Century” initiative to modernize and coordinate the 
regulation of pharmaceutical manufacturing [1]. This cGMP initiative should create a regulatory 
framework that encourages and enables the pharmaceutical industry to early adopt modern 
tools and facilitate the implementation of robust manufacturing processes that ensure 
continuously high product quality. Furthermore, industry`s “application of modern quality 
management techniques, including implementation of quality system approaches” [1] should be 
facilitated. In context of this cGMP initiative, the FDA announced and published several 
“Guidance for Industry” papers, i.a. “PAT - A Framework for Innovative Pharmaceutical 
Development, Manufacturing, and Quality Assurance” [2] and “Quality Systems Approach to 
Pharmaceutical cGMP Regulations” [3]. Based on the cGMP initiative with its relating guidance 
documents and in line with ICH Q8 (2009) [4], “Quality by design” (QbD) for pharmaceuticals 
was introduced. In contrast to the traditionally applied end product testing approach, QbD 
promotes to build quality into the product by design rather than testing it at the end [5]. According 
to ICH Q8 (2009), QbD is defined as “A systematic approach to development that begins with 
predefined objectives and emphasizes product and process understanding and process control, 
based on sound science and quality risk management” [4]. This approach, based on scientific 
knowledge, thorough process and product understanding and control accompanied by 
appropriate quality risk management principles, can enhance pharmaceutical product 
development [5]. Two critical elements of QbD are the definition of a Design Space and the 
application of Process Analytical Technology (PAT) tools. According to ICH Q8 (R2), a Design 
Space is defined as “The multidimensional combination and interaction of input variables (e.g., 
material attributes) and process parameters that have been demonstrated to provide assurance 
of quality” [4]. Consequently, working in the ranges of the Design Space is not considered as a 
change by the authorities and does not require a post approval change request [4].  
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In 2005, a QbD pilot program for small molecules started, followed by a comparable pilot 
program for biologics. By mid 2011, 11 design space approvals were submitted for small 
molecules and none for biologics. The first biologic approved by the FDA with design space was 
Genentech`s Gazyva in 2013. The complexity of the manufacturing process for a biologic 
reflects the challenge of defining the predefined objectives and a design space. This might be 
one reason, why the implementation of QbD for biologics seems to require more time and 
discussion than for small molecules. For example, it is more straightforward to validate a 
chemical synthesis compared to a cell culture production process [6]. 
Biologics, e.g. proteins, require a unique 3-D structural conformation for their activity. 
Furthermore, proteins are prone to several degradation processes during manufacturing, e.g. 
deamidation, oxidation, hydrolysis, aggregation, and denaturation. Due to these physical and 
chemical instabilities, biological products need to be administered parenterally and pose 
challenges for adequate shelf life time of the final product. Thus, a lot of effort was put into 
formulation development [6]. However, if a biological product does not exhibit enough stability 
in liquid formulation, freeze-drying, also named as lyophilization, has become the method of 
choice to stabilize these temperature sensitive products [7, 8].  
Freeze-drying is based on heat and mass transfer principles and fits well into the QbD concept 
[9]. During a freeze-drying process, comprising the freezing, primary and secondary drying step, 
primary drying is the longest and most critical step, which can result in compromised product 
quality, e.g. by collapse, resulting in higher residual moisture. As collapse occurs if the product 
temperature (Tp) exceeds the critical collapse temperature (Tc), freeze-drying requires process 
specific optimization to ensure that Tp does not exceed Tc during primary drying and that primary 
drying is completed [8]. Therefore, design spaces for primary drying intend to keep Tp below Tc 
by a safe margin [9]. However, one major challenge for this approach is that Tp cannot directly 
be controlled. Tp depends on various factors, mainly the set shelf temperature (Ts) and the 
chamber pressure (pc), but also on the so-called vial heat transfer coefficient (Kv) and the mass 
flow resistance (e.g. cake resistance or stopper resistance). Both academia and industry have 
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been interested in understanding the correlation between Ts, pc, Kv and the resulting Tp to 
optimize freeze-drying processes. With the above mentioned QbD initiative, the need for a 
thorough process understanding increased. Various studies and approaches to optimize and 
model freeze-drying cycles have been performed [10-15].  
Besides maintaining product quality, the optimization of freeze-drying cycles with respect to 
economic drying times was another aim. This means that the safety margin between Tp and Tc 
should be as small as possible and primary drying as fast as possible. Thus, the accurate 
monitoring of Tp and the determination of the end of primary and secondary drying are crucial 
to assure product quality and process economy [8]. Consequently, the need for rigorous product 
monitoring and process analytical technology (PAT) tools during cycle development is high. In 
the field of PAT tools for freeze-drying, extensive research has been performed. Tools like 
thermocouples [16, 17], Manometric Temperature Measurement (MTM) [18-21], Near-Infrared 
spectroscopy [22-26], Raman spectroscopy [22, 27], Tunable diode laser absorption 
spectroscopy (TDLAS) [28-30], or an optical fiber system (OFS) [31] have been introduced and 
studied. Within the introduction of Chapter V, some of the named PAT tools are discussed in 
more detail.  
In the context of QbD and the request for new PAT tools, two new technologies for freeze-drying 
gained interest in the last years: controlled ice nucleation (CN) and heat flux measurements. 
These two technologies raised great expectations for freeze-drying cycle optimization and 
control and their potential benefits have been discussed.  
CONTROLLED NUCLEATION (CN) 
CN enables the control of the ice nucleation temperature (TN) (otherwise a random event), which 
gives more control over the freeze-drying process. Additionally, TN significantly impacts process 
performance: High TN results in larger ice crystals, which leave behind larger pores during 
sublimation and thus lower product resistance. This leads to reduced primary drying times. 
However, larger pores reciprocally result in a lower specific surface area (SSA), which hinders 
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desorption during secondary drying and can cause a higher residual moisture of the product. 
Vice versa, low TN causes small ice crystals, resulting in small pores and longer primary drying 
times, but faster desorption during secondary drying [32, 33].  
Furthermore, CN could help to ensure product quality during scale-up. As TN is typically higher 
in a development environment where more particles can be introduced into the product that 
function as nucleation sites, Tp can be lower due to larger pores causing less resistance. For 
successful process transfer, it needs to be considered that the product in an almost particle free 
production environment tends to nucleate at lower TN and thus Tp will be higher, which poses 
the risk for collapse. With CN, TN could be defined and kept the same in development and 
production scale.  
Another benefit of CN that has been discussed is its impact on homogeneity within a batch and 
between batches. The stochastic nature of ice nucleation could introduce e.g. vial-to-vial 
heterogeneities and as mentioned above cause variability between batches. With the control of 
TN, all vials of a batch nucleate at the same time, at the same temperature; consequently, the 
drying behavior and product homogeneity should be improved. Up to now, two approaches to 
assess batch homogeneity, in this context, have been reported: (i) analysis of individual vials 
and (ii) batch representative methods. Rambhatla et al. [32] and Fang et al. [34], for example, 
compared the standard deviation of BET measurements (n=3) and LDH activity (n=6), 
respectively, of CN processed lyophilizates with randomly nucleated (RN) products to assess 
batch homogeneity. Given the small number of replicates, although taken from critical positions 
within the freeze-dryer (edge vials and center vials), extrapolation to a full batch could be 
challenging. In contrast, Passot et al. [35] or Oddone et al. [36] determined the average drying 
behavior of a complete batch by comparing the absolute value of the slope of the Pirani gauge 
profile (n=100) or by comparing the onset-offset time of the pressure ratio curve (n=70), 
respectively. One drawback of this method is that it only allows for determination of the 
homogeneity at the end of primary drying but not of the final product.  
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Besides the already mentioned reduction of primary drying time, facilitation of process transfer 
and improvement of intra-and inter-batch homogeneity, it was also suggested that the change 
in SSA could impact product quality. One the one hand, as pointed out above, a low SSA hinders 
desorption during secondary drying and could result in higher residual moisture of the product 
if the process is not adjusted. On the other hand, a reduced SSA exposes the protein to a 
smaller interface, which could theoretically be beneficial for interface sensitive proteins. This 
was confirmed by Schersch et al. [37-39], who found that a low SSA generated by collapse can 
be beneficial for the stability of pharmaceutically relevant proteins (e.g. monoclonal antibody 
type IgG1, Actilyse®, LDH). Another interesting aspect of a lyophilized product with a low SSA 
is the impact on reconstitution behavior. Geidobler et al. [40] applied controlled nucleation to 
highly concentrated protein formulations, as those often result in very long reconstitution times, 
and showed that besides reducing primary drying time, the resulting large pores could also 
improve wetting of the cake and thus shorten reconstitution times of a highly concentrated 
monoclonal antibody (mAb) formulation.  
Today, various methods to induce CN are commercially available. The two key techniques are 
ice fog methods, e.g. FreezeBooster® (Millrock Technology), LyoCoN (Martin Christ), and 
VERISEQ® nucleation system (IMA life/Linde) and methods based on pressure changes, such 
as ControLyoTM (SP Scientific), SynchroFreeze (Hof) and a recently published method from 
OPTIMA pharma [41]. In a review, Geidobler et al. [42] summarized and discussed the different 
approaches to induce ice nucleation considering e.g. scalability, need of retrofitting, application 
to aseptic environments and efficiency.  
HEAT FLUX MEASUREMENTS 
Heat flux sensors have been used by e.g. plastics-, automotive-, or solar energy industry [43], 
and are now introduced to pharmaceutical freeze-drying, by Millrock Technology Inc., as a new 
approach to monitor Tp and process end points by measuring the heat flux between the 
freeze-dryer shelf and vial(s) [44]. Generally, these sensors are able to measure heat flux 
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resulting from different heat transfer, e.g. conductive, convective, and radiation heat transfer 
[43]. As, for the application in freeze-drying, the sensor is placed between the vials and the 
shelf, it mainly measures heat transferred by conduction and convection [44].  
Theoretically, with heat flux measurements all steps of a freeze-drying process could be 
monitored, as throughout the freeze-drying cycle heat transfer always takes place. However, 
the heat flux direction changes. During freezing, the heat is transferred from the warmer vial to 
the colder shelf surface, which results in a negative heat flux. While, during primary and 
secondary drying, heat flux is positive as heat flows from the shelf to the vials.  
As heat flux can only be determined as long as there is a temperature difference between heat 
source and heat sink, heat flux measurements could also be used to determine the end of 
primary drying, as heat flux approaches zero when the vials reach Ts. Additionally, heat flux 
measurements could indicate the end of ice crystallization during freezing by a change in heat 
flux direction, because the generated exothermic heat warms the vial during ice formation, 
whereas the vial temperature approaches the Ts after the crystallization event [45].  
Moreover, when heat flux data are combined with thermocouple data, important parameters for 
process development and control such as the vial heat transfer coefficient (Kv) can be assessed. 
Currently, time consuming gravimetrical approaches are used for Kv determination. Heat flux 
measurements could provide a fast, simple and non-invasive alternative. However, it should be 
noted that the vial heat transfer coefficient determined by heat flux measurement (Kv(heat flux)) 
is based mainly on conduction and convection heat and thus differs from the Kv determined by 
gravimetrical measurements (Kv(gravimetrically)) and calculated as described by Pikal et al. 
[10], which takes, in addition to conduction and convection, also radiation into account. 
Additionally, mass flow per vial, mass flow of the entire batch, fraction of removed mass and the 
product resistance (Rp) could be calculated based on determined heat flux data. Ultimately, from 
Rp, Tp at the sublimation interface could be calculated. 
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Besides process monitoring, it was also suggested, that the heat flux can be used to control 
freeze-drying processes by adjusting the shelf temperature set point based on the measured 
heat flux in order to achieve maximum heat transfer while Tp is kept below the critical product 
temperature. 
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I.2 OBJECTIVES AND OUTLINE OF THE THESIS 
The claimed potential of CN to improve product quality (by a low SSA) and facilitate process 
transfer raised great expectations for the application of CN for QbD. However, in practice, we 
face some challenges when we want to reach these goals by CN, e.g. how to non-destructively 
monitor successful performed CN and validate CN processes. As not every method can easily 
be implemented in development and production scale freeze-dryers, the question arises if 
different CN methods result in comparable product quality attributes. Furthermore, it is of high 
interest if besides the reduction in reconstitution time, CN could improve other product quality 
attributes.  
The first part of this thesis, Chapter II to IV, comprises the critically and systematically 
assessment of the open challenges and questions regarding CN by using different ice fog 
techniques. In Chapter II, the objective was to combine CN with aggressive primary drying and 
investigate the impact of this combination on certain product properties, e.g. cake appearance, 
morphology, specific surface area, residual moisture, and reconstitution time of highly 
concentrated protein formulations.  
In Chapter III, the question was assessed, if besides the reduction in reconstitution time, CN 
could be beneficial for other product quality attributes related to a low SSA, such as physico-
chemical stability of a mAb. The performed study comprises the long-term storage of two mAbs 
formulated at a high and low concentration in a sucrose-based formulation. The current state of 
the art to protect proteins from interfaces is the use of polysorbate [46-48], thus, the effect of 
CN in formulations with and without polysorbate was investigated additionally.  
In Chapter IV, challenges related to the practical application of CN were addressed. First, to 
solve the question how to non-destructively monitor successfully performed controlled 
nucleation and thus, be able to validate a CN process, frequency modulated spectroscopy was 
evaluated as PAT tool for CN success and as a method to study batch homogeneity. Second, 
the question if different ice fog methods result in comparable product quality attributes was 
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evaluated by comparing the optical appearance, microscopic structure, SSA and RM of 
lyophilizates generated by three different ice fog methods. Moreover, based on findings of the 
study presented in Chapter III, we investigated factors that, besides TN, impact the SSA of a 
lyophilizate, when CN is applied.  
In the second part of this thesis, Chapter V, heat flux measurements were evaluated regarding 
their usage as a new PAT tool for freeze-drying. Therefore, the performance and suitability of 
heat flux measurements for freeze-drying process monitoring under pharmaceutically relevant 
conditions was assessed. Heat flux measurements were compared to current state of the art 
techniques to monitor freeze-drying processes, such as comparative pressure measurement 
thermocouple readings or Karl Fischer titration. Furthermore, the accuracy of the determined 
Kv(heat flux) was investigated by calculating the product temperature out of Kv(heat flux) and 
comparing the calculated product temperature with actual thermocouple readings. 
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II.1 INTRODUCTION 
Since Searles et al. [1] identified the ice nucleation temperature (TN) as a relevant factor for the 
primary drying (PD) rate during lyophilization, the freezing step gained more attention in 
freeze-drying cycle optimization. A higher TN causes formation of larger ice crystals, which result 
in larger pores. These larger pores facilitate sublimation due to reduced product resistance and 
thus, speed-up PD [1-3]. But larger pores come with reduced specific surface area (SSA), which 
induces slower water desorption during secondary drying (SD) and thus, could cause higher 
residual moisture (RM) levels of the final product [2, 4].  
Consequently, methods emerged to control TN by controlled nucleation of ice (CN). Rowe et al. 
[5] first proposed the use of ice crystals as seeds to induce ice nucleation purging cold nitrogen 
gas into the high humidity environment of the drying chamber to form an ice fog after the vials 
have achieved the temperature at which nucleation is desired. Rambhatla et al. [4] developed 
this ice fog technique further and achieved complete nucleation of all vials within 5 min. In a 
follow-up study, Patel et al. [6], could reduce the time needed for complete nucleation to 1 min. 
Geidobler et al. [7] presented an easy approach to induce ice nucleation by a modified ice fog 
method. Their technique does not require liquid nitrogen or any modification of the freeze-dryer. 
After equilibration of the vials at the desired TN, the freeze-dryer is depressurized to e.g. 
3.7 mbar and subsequently vented through the cold condenser back to atmospheric pressure. 
Thus, ice crystals are formed in-situ in the chamber, which results in a very fast ice fog 
distribution. The supercooled vials all nucleated within about 5 s. Millrock Technology Inc. 
introduced a similar ice fog method, the FreezeBooster® [8]. After equilibration of the product 
vials, the freeze-dryer is depressurized to approximately 66 mbar. In contrast to Geidobler et 
al., before venting, the isolation valve between the chamber and the condenser is closed, the 
condenser is backfilled to atmospheric pressure and water steam is sprayed into the cold 
condenser chamber to generate ice crystals. By opening the isolation valve, the ice fog is 
generated and transferred into the chamber. Geidobler and Winter [9] reviewed the different 
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approaches to induce ice nucleation in detail. Additionally, they provide an overview of the 
differences in product characteristics, such as SSA and RM, between samples nucleated in a 
controlled way or randomly. 
Various studies investigated the impact of TN on PD rate, product resistance, and SSA [2, 4, 6, 
10-12]. Previously, we applied CN for the first time to highly concentrated protein formulations 
by using the method described by Geidobler et al. [7, 13]. The time for PD was reduced and the 
resulting large pores facilitated cake wetting and faster reconstitution. A rather conservative 
freeze-drying cycle with product temperatures (Tp) well below the glass transition temperature 
(Tg`) was used to avoid any change of the ice crystal structure generated by CN due to potential 
micro collapse. However, for highly concentrated protein formulations, the actual collapse 
temperature (Tc) can be significantly higher than Tg`, which enables PD above Tg` without 
collapse [14-16]. Such an aggressive PD remarkably reduces PD times.  
In this study, we combined CN, using the FreezeBooster® method, with aggressive PD to further 
reduce PD time of a highly concentrated protein formulation without changing product 
characteristics such as SSA and RM. We developed a freeze-drying cycle with Tp above Tg` but 
below Tc using bovine serum albumin (BSA) and compared the product characteristics of those 
lyophilizates with the lyophilizates obtained from the conservative PD process of our previous 
study [13]. The developed aggressive PD protocols were than applied to a highly concentrated 
mAb formulation. The product characteristics of the mAb lyophilizates processed by the 
aggressive PD protocols were compared to the ones generated by the conservative PD 
protocol. 
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II.2 MATERIALS AND METHODS 
II.2.1 MATERIALS 
An IgG1 mAb, formulated at 161.2 mg/ml in a 10 mM histidine buffer (pH 5.4) was used in this 
study. BSA was purchased from Sigma-Aldrich (Munich, Germany). Sucrose was kindly 
provided by Suedzucker (Plattling, Germany). Di-sodium hydrogen phosphate, sodium 
dihydrogen phosphate, and trehalose were purchased from VWR (Ismaning, Germany). All 
chemicals were of analytical grade.  
Low protein binding polyvinylidenfluorid (PVDF) 0.22 µm filters were purchased from Merck 
Millipore (Schwalbach, Germany). 2R glass type I tubing vials were kindly provided by MGlas 
AG (Münnerstadt, Germany). Rubber stoppers, 13 mm (Westar® RS, 4023/50, bromobutyl, 
grey, FluoroTec B2-40 coating) were kindly supplied by West Pharmaceutical Services 
(Eschweiler, Germany). Standard aluminum crimp caps, compatible with 13 mm stoppers, were 
used. All vials and stoppers were washed manually three times with highly purified water (Milli-
Q, Merck Millipore, Hertfordshire, United Kingdom), autoclaved at 121 °C for 20 min and dried 
at 80 °C.  
II.2.2 SAMPLE PREPARATION 
BSA was formulated at 193 mg/ml in a 10 mM phosphate buffer (pH 7.4) with 5% sucrose. The 
mAb formulation was completed by adding 5% sucrose. The concentration of all formulations 
was determined at 280 nm using a Nanodrop 2000 UV photometer (Thermo Scientific, 
Wilmington, DE, USA). Sample aliquots of 1.0 ml of the BSA formulation and 0.37 ml of the mAb 
formulation were manually filled and the vials were semi-stoppered manually.  
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II.2.3 LYOPHILIZATION 
Lyophilization was performed using a Millrock Magnum pilot scale freeze-dryer (Millrock 
Technology, Kingston, NY, USA). During freeze-drying the vacuum was controlled by a 
capacitance gauge. For Tp monitoring, thermocouples were used. End of PD was detected by 
comparative pressure measurement. The freeze-dryer automatically proceeded into SD when 
the detected pressure difference was less than 1 mTorr (0.0013 mbar). By default, the vials 
were stored at 5 °C after completion of the freeze-drying cycle. Stoppering was initiated 
manually after the chamber pressure (pc) was backfilled to 600 Torr (800 mbar). After unloading 
the vials were crimp capped.  
Freezing was performed either by CN using the Millrock FreezeBooster® [8] in manual mode 
(Millrock Technology, Inc, Kingston, NY; USA) or a ramp freezing protocol (RN). For CN, the 
vials were equilibrated for 2 h at the aimed nucleation temperature of -5 °C. Immediately after 
controlled nucleation, the shelf temperature (Ts) was ramped to -60 °C at 1 °C/min. RN samples 
were equilibrated at 2 °C for at least 1 h before the shelf temperature was lowered to -60 °C at 
1 °C/min. A hold time of 120 min at -60 °C was applied to all freezing protocols prior to initiating 
primary drying.  
Different PD and SD parameters (Ts and pc) for aggressive drying were evaluated to achieve a 
Tp between Tg` and Tc and to meet the same target RM and SSA values as in the previous study 
[13] (Table II-1).   
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Table II-1: Overview of evaluated PD and SD parameters to optimize the aggressive PD protocol. 
Lyo Cycle 
(LC) 
Primary drying Secondary drying 
 
Temperature profile 
Chamber 
pressure 
Temperature 
profile 
Chamber 
pressure 
Duration 
[h] 
CN1 20 °C (0.5 °C/min) 
750 mTorr 
(1 mbar) 
25 °C  
(0.1 °C/min)* 
50 mTorr 
(0.06 mbar) 
6 
CN2 
20 °C (0.5 °C/min);  
hold time: 30 min;  
0°C (1 °C/min) 
30 °C  
(0.1 °C/min) 
6 
CN3 
20 °C (0.5 °C/min);  
hold time: 30 min;  
0 °C (1 °C/min) 
30 °C 
(0.05 °C/min) 
6 
CN4 0 °C (0.5 °C/min) 
30 °C  
(0.1 °C/min) 
6 
RN1 20 °C (0.5 °C/min) 
30 °C  
(0.1 °C/min) 
6 
RN2 0 °C (0.5 °C/min) 
30 °C  
(0.1 °C/min) 
6 
RN3 
20 °C (0.5 °C/min);  
hold time: 30 min;  
0 °C (1 °C/min) 
30 °C  
(0.1 °C/min) 
6 
RN4 
20 °C (0.5 °C/min);  
no hold time; 
0 °C (1 °C/min) 
30 °C  
(0.1 °C/min) 
6 
RN5 
20 °C (0.5 °C/min);  
hold time: 120 min;  
0 °C (0.1 °C/min) 
562 mTorr 
(0.75 mbar) 
40 °C  
(0.1 °C/min)* 
6 
RN6 
20 °C (0.5 °C/min);  
hold time: 90 min;  
-10 °C (0.2 °C/min) 
375 mTorr 
(0. 5 mbar) 
40 °C  
(0.1 °C/min) 
3 
RN7 
20 °C (0.5 °C/min);  
hold time: 30 min;  
-10 °C (0.2 °C/min) 
75 mTorr 
(0.1 mbar) 
40 °C  
(0.1 °C/min) 
1 
Conservative 
PD CN [13] 
-22 °C (0.5 °C/min) 
50 mTorr 
(0.066 mbar) 
25 °C 
(0.1 °C/min) 
6 
* For mAb formulation secondary drying temperature was set to 30 °C (0.1 °C/min) for 6 h. 
II.2.4 SCANNING ELECTRON MICROSCOPY (SEM) 
SEM was used to study the morphology of the lyophilizates (JSM-6500F Field Emission Electron 
Microscope, Jeol, Eching, Germany). The freeze-dried cake was broken with a spatula and the 
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generated pieces were fixed with carbon conductive cement on a sample holder such that the 
breakage border could be analyzed.  
II.2.5 KARL FISCHER TITRATION (KF) 
KF was used to determine the RM of the freeze-dried products. BSA samples were analyzed 
by the direct injection method using a 737 KF Coulometer (Metrohm, Filderstadt, Germany). 
Approximately 2.5 ml of anhydrous methanol was added to the sample. To extract the water, 
the sample was placed in an ultrasonic bath for 10 min. An aliquot of 1 ml was injected into the 
titrator. Results were calculated as relative water content (m/m). For the mAb samples, an Aqua 
40.00 coulometric titrator combined with a headspace module (Analytik Jena GmbH, Jena, 
Germany) was used for the analysis. About 20 mg of sample was weighed into a 2R glass vial 
under a glovebox (r.h. ≤ 5%). The sample was analyzed at 150 °C. Prior to the measurements, 
a system suitability test was performed daily by measuring a pure water standard (Apura 1 water 
standard oven 1.0, Merck KGaA).  
II.2.6 FREEZE-DRYING MICROSCOPY (FDM) 
FDM was used to determine Tc (FDSC 196, Resultec, Illerkirchberg, Germany). A sample 
aliquot of 2 µl was pipetted in a quartz crucible. By a horseshoe-shaped spacer ring a defined 
distance between quartz crucible and cover slip was granted. The sample was frozen with a 
rate of 1 K/min to -50 °C. After exhausting to a vacuum of 0.1 mbar, the sample was heated at 
1 K/min to 5 °C. During the heating step, images were taken every second. The temperature 
when the first translucent dots appeared was considered as collapse onset temperature 
(Tc,onset). The full collapse temperature (Tc) was determined at the temperature where a full 
loss of structure occurred. 
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II.2.7 DIFFERENTIAL SCANNING CALORIMETRY (DSC) 
The glass transition temperatures Tg´ of the frozen product was determined by DSC (Mettler 
Toledo DSC821e, Mettler Toledo, Giessen, Germany). Approximately 30 µl of the product were 
pipetted into an aluminum crucible (Mettler Toledo, Giessen, Germany). The samples were 
cooled to -40 °C with 5 K/min and further to -50 °C with 2 K/min. After an isothermal hold of 
2 min, samples were re-heated to 20 °C with a heating rate of 20 K/min. The midpoint of the 
endothermic shift of the baseline during the heating scan was taken as Tg`.  
II.2.8 BET ANALYSIS 
The SSA of the lyohilizates was analyzed by the BET method using an Autosorb-1 
(Quantachrome Instruments, Germany). Approximately 100 mg sample was crushed with a 
spatula and weighed into a glass sample tube. Degassing was performed for at least 2 h at 
25 °C. Subsequently, Krypton sorption measurement was performed at 77.3 K. An 11-data point 
adsorption curve covering a p/p0 region from 0.05 to 0.3 was recorded. The data points were 
evaluated according to the multipoint BET-method. 
II.2.9 RECONSTITUTION PROCEDURE AND DETERMINATION OF 
RECONSTITUTION TIME 
To reconstitute the lyophilizates, the vials were placed on an orbital shaker (VWR, Ismaning, 
Germany) and the desired amount of highly purified water was pipetted into the middle of the 
lyophilized cake and the samples were shaken at 400 rpm. The time until a clear solution 
resulted was recorded as reconstitution time. BSA samples were reconstituted with 1.6 ml and 
mAb lyophilizates with 0.32 ml. The reconstitution volume for the BSA samples was increased 
to avoid that dissolution effects impact the reconstitution time (as found in our previous work) 
[13]. The required volume for reconstitution of the mAb lyophilizates was calculated based on 
the density of the liquid formulation and the total solid content.  
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II.2.10 DATA ANALYSIS AND ILLUSTRATION 
Throughout the manuscript error bars represent the standard deviation based on triplicates. If 
no error bars are shown, only one sample was analyzed due to material constraints.   
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II.3 RESULTS 
II.3.1 DSC AND FDM 
At first, Tg` and Tc of all samples were characterized. With increasing BSA concentration higher 
Tg` and Tc values were determined except for BSA 100 mg/ml. As the Tg` was followed directly 
by the onset of the melting, it was not possible to determine Tg` at BSA concentrations higher 
than 100 mg/ml (Figure II-1) and for the mAb formulation at 161.2 mg/ml. Consequently, Tg` 
values for 150 mg/ml and 193 mg/ml BSA were extrapolated by linear regression (Table II-2 
and APPENDIX Figure VIII-1). 
 
Figure II-1: Thermograms of BSA formulations ranging from 10 mg/ml to 200 mg/ml. The arrows point towards the baseline 
shift, which indicates Tg`.   
CONTROLLED ICE NUCLEATION FOLLOWED BY AGGRESSIVE PRIMARY DRYING DURING 
LYOPHILIZATION OF HIGHLY CONCENTRATED PROTEIN FORMULATIONS 
25 
Table II-2: Tg` and Tc values for formulations with different BSA concentrations and the mAb formulation. 
Formulation Tg` [°C] Tc [°C] 
BSA 10 mg/ml -30.5 -24.5 
BSA 20 mg/ml -27.5 -18.7 
BSA 50 mg/ml -26.8 -14.2 
BSA 75 mg/ml -23.2 -13.4 
BSA 100 mg/ml -22.9 -15.1 
BSA 150 mg/ml -18.2* -11.9 
BSA 200 mg/ml -14.7* -10.1 
mAb 161 mg/ml ------ -8.1 
* extrapolated by linear regression (R2=0.9776)  
II.3.2 PRODUCT TEMPERATURES AND PRIMARY DRYING TIMES  
Table II-3 provides the time required to complete PD for the tested lyo cycles. All lyo cycles with 
aggressive PD showed a remarkable reduction in PD time compared to the conservative drying 
method of Geidobler et al. [13].  
For BSA formulations, the shortest primary drying time of about 4 h could be achieved by the 
most aggressive lyo cycles, CN1 and RN1, independent from the nucleation protocol. The least 
aggressive protocols, CN4 and RN2, revealed the longest primary drying times but PD was still 
faster compared to the conservative PD of Geidobler et al. [13]. Duration of PD was only slightly 
affected by the nucleation protocol. Compared to RN product, the Tp of the CN product is about 
2-3 °C lower e.g. CN1 vs. RN1, CN4 vs. RN2, and CN2 vs. RN3. 
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Table II-3: Tp after 1 h of PD and PD durations of the lyo cycles. 
Formulation Lyo cycle 
Product temperature 
[°C] after 1 h of PD 
PD duration [h]* 
BSA 
CN1 -9.3 4.0 
CN2 -14.5 6.1 
CN3 -14.1 6.8 
CN4 -16.5 9.3 
RN1 -6.5 3.7 
RN2 -14.2 7.4 
RN3 -12.8 5.4 
RN4 -10.6 6.3 
RN5 -9.9 5.0 
RN6 -11.3 4.7 
RN7 -20.8 10.0 
Conservative CN  -39.9 18.0 
mAb 
CN1 +3.1 3.4 
RN2 -15.5 6.4 
RN5 -3.4 3.1 
Geidobler et al 
[13] 
CN  
(BSA 193.9 mg/ml) 
-38.7 (7 h PD) 24.2+ 
CN  
(mAb 161.2 mg/ml) 
-33.2 (7 h PD) 20.0+ 
RN 
(mAb 161.2 mg/ml) 
-30.5 (7 h PD) 25.0+ 
* the time span between the time point when TS reached the set point for PD until comparative pressure 
measurement indicated the end of PD. 
+ end of PD was determined by thermocouple readings. 
 
Independent of the nucleation protocol, both more aggressive lyo cycles, CN1 and RN5, 
resulted in a PD time of about 4 h for the mAb formulation. For the less aggressive RN2 cycle 
a longer PD time was detected compared to CN1 and RN5. A markedly higher Tp was measured 
for much more aggressive CN1 conditions compared to RN5. 
II.3.3 CAKE APPEARANCE AND SEM 
The cakes of CN and RN lyophilizates markedly differed in appearance. CN lyophilizates 
exhibited a more porous, loose and shiny structure with substantial crack formation (Figure II-2A 
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and APPENDIX Figure VIII-2). In contrast, RN lyophilizates showed a compact cake with minor 
shrinkage in height and diameter, a shiny surface and only tiny cracks (Figure II-2B). The BSA 
CN cakes were light-yellow in color, whereas the BSA RN cakes were slightly beige. Both types 
of mAb lyophilizates appeared white (Figure II-2 and APPENDIX Figure VIII-2). The BSA and 
mAb cake appearance was independent of the PD protocols (APPENDIX Figure VIII-2).  
  
Figure II-2: Photographs of a CN1 lyophilizate (A) and a RN1 lyophilizate (B) of the BSA formulation. 
After macroscopic characterization, microscopic analysis of selected lyophilizates was 
performed by SEM. All lyophilizates had a sponge like morphology in common (Figure II-3). The 
CN lyophilizates showed larger pores compared to the RN products. RN2 cake pores appeared 
slightly larger than the pores of RN5 lyophilizates. No effect of protein or PD protocol could be 
detected.  
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Figure II-3: SEM images of CN1, RN2, and RN5 of the BSA and mAb formulation and SEM images of CN and RN runs 
followed by conservative PD of the mAb formulation.  
II.3.4 BET AND KARL FISCHER  
The lyophilizates were analyzed by Krypton gas adsorption to determine the SSA and Karl 
Fischer to assess RM (Figure II-4 and Figure II-5). Corresponding to the larger pores seen in 
SEM, CN lyophilizates showed a lower SSA and higher RM compared to RN products (Figure 
II-4 and Figure II-5).  
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The SSA of the BSA formulations dried with conservative PD after CN, using the Millrock 
freeze-dryer, was comparable to one of the lyophilizates described by Geidobler et al. [13] 
(Figure II-4A). All aggressive PD CN protocols (CN1-4) resulted in a slightly lower SSA 
compared to conservative PD without a difference in SSA between CN1, 2, 3, and 4. SSA of 
RN2 and RN4 samples met the SSA of lyophilizates processed by the conservative PD of 
Geidobler et al. [13]. RN1 and RN3 led to slightly lower and RN5, 6, and 7 to markedly lower 
SSA values. The RM of CN cakes produced by Geidobler et al. [13] was lower compared to the 
conservative PD CN protocol as the secondary drying temperature differed (Geidobler et al.[13] 
=30 °C for 6 h; Conservative PD CN= 25 °C for 6 h) (Figure II-4B). This also explains the higher 
RM for CN1 compared to CN2, 3, and 4. RN1 to RN4 processed lyophilizates resulted in similar 
RM values as RN samples described by Geidobler et al. [13]. In RN5, 6, and 7 secondary drying 
was performed at 40 °C, which resulted in lower RM values. 
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Figure II-4: Results of BET (A) and KF (B) measurements of all lyo cycles using the BSA formulation and results by 
Geidobler et al. [13].  
The SSA of both CN1 and RN2 and 5 mAb lyophilizates was lower as compared to the results 
for products dried with the less aggressive approach by Geidobler et al. [13] (Figure II-5A). 
Whereas the RM content of CN1 lyophilizates was slightly higher than the RM detected by 
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Geidobler et al. [13] for CN (Figure II-5B), RN2 and RN5 rendered products with lower RM 
compared to Geidobler et al. [13] for RN.  
 
Figure II-5: Results of BET (A) and KF (B) measurements of all lyo cycles using the mAb formulation. Geidobler et al [13] 
mAb results were included for comparability.  
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II.3.5 RECONSTITUTION TIMES 
For the mAb formulation also reconstitution times were determined (Figure II-6). Comparable to 
Geidobler et al. [13], CN resulted in a three-times faster cake dissolution compared to RN. The 
aggressive PD protocols showed shorter reconstitution times compared to the conservative PD.  
 
Figure II-6: Results of reconstitution times determination of the mAb lyophilizates. Geidobler et al. [13] mAb results were 
included for comparability. 
  
CONTROLLED ICE NUCLEATION FOLLOWED BY AGGRESSIVE PRIMARY DRYING DURING 
LYOPHILIZATION OF HIGHLY CONCENTRATED PROTEIN FORMULATIONS 
33 
II.4 DISCUSSION 
In the first part of this study freeze-drying cycles with aggressive primary drying were developed 
for a CN process using the FreezeBooster® method, as well as for a RN process. The 
aggressive primary drying should not change the product properties compared to the 
lyophilizates prepared by conservative primary drying in our previous study [13]. We 
subsequently applied the developed aggressive freeze-drying to a highly concentrated mAb 
formulation and again compared the product properties to our previous results. 
II.4.1 DEVELOPMENT OF A FREEZE-DRYING CYCLE WITH AGGRESSIVE 
PRIMARY DRYING 
As we used the FreezeBooster® method instead of the method described by Geidobler et al. [7], 
which was used in our previous study, we first evaluated the impact of the change in CN method 
on product properties. Therefore, we performed CN with the FreezeBooster® and used the 
conservative drying protocol of our previous study [13]. However, by accident, the secondary 
drying temperature was set to 25 °C instead of 30 °C. Whereas the SSA of conservative PD CN 
(Millrock) was comparable to the SSA determined by Geidobler et al. [13] (Figure II-4A), RM 
was higher (Figure II-4B) due to the lower secondary drying temperature. We concluded that 
the two CN methods, performed on two freeze-dryers, resulted in comparable product 
properties. 
For aggressive primary drying, the target Tp was to be between Tg` and Tc. Thus, Tp during PD 
should be below -10.1 °C but above -14.2 °C for the BSA formulation and slightly below -8.1 °C 
for the mAb formulation. For the mAb formulation Tg` was not determined. For the BSA 
formulations, the Tg` of the high concentration formulation had to be extrapolated from the 
results of a concentration series. Overall, Tg` was several degrees below Tc, according to Patel 
et al. [15]. 
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As the vapor pressure over ice at -12 °C is 1630 mTorr (2.17 mbar) and the freeze-dryer allows 
adequate pressure control below 1000 mTorr, 750 mTorr (1 mbar) were defined as the most 
aggressive pc to be used. To achieve a Tp of approximately -11 °C the Ts was set to 20 °C for 
CN1 and RN1 (Table II-1). In the case of CN1, Tp marginally exceeded Tc by 0.8 °C, which is 
within the accuracy of the used thermocouples (Table II-3). Neither cake appearance nor cake 
morphology indicated collapse and were comparable to the CN lyophilizates processed by the 
conservative PD. However, SSA of CN1 lyophilizates was slightly lower than that of 
conservative PD CN lyophilizates, which could indicate micro-collapse (Figure II-4A). As Tp 
increases with ongoing PD due to the increasing dry layer resistance [17], Ts of CN2 was 
lowered after 30 min PD to 0 °C. Although Tp was well below Tc and even below the extrapolated 
Tg`, the determined SSA for CN2 products was comparable to CN1 lyophilizates. As the change 
in PD protocol did not result in an increase in SSA, we supposed that SD might be causing the 
slight differences in SSA and evaluated a slower ramp into SD with CN3 and a lower Ts (0 °C) 
in CN4. However, also these parameters resulted in the same SSA. Based on CN1-4, which all 
showed similar cake appearance and morphology as conservative PD products, we concluded 
that CN defines the ice crystal size during freezing and with this the resulting SSA, thus the 
slightly lower SSA of the aggressive PD lyophilizates was not caused by micro-collapse. 
Additionally, RM values of CN2 and CN3 lyophilizates were comparable to the CN lyophilizates 
of Geidobler et al. [13]. CN4 samples showed slightly higher RM values, which might be caused 
by a higher RM content after primary drying due to the lower Ts. As CN1 led to the shortest PD 
time and the Tp closest to -10.1 °C, CN1 PD settings were chosen as aggressive PD protocol 
for the CN process.  
For the development of an aggressive PD protocol for the RN process, the same starting point 
as for the CN process was chosen with a pc of 750 mTorr and a Ts of 20 °C. However, in case 
of RN1, Tp exceeded Tc by 3.6 °C compared to the 0.8 °C of the CN process, because the higher 
product resistance due to the smaller pores causes higher Tp. Although, macroscopically, no 
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collapse of the freeze-dried cake could be detected, a reduced SSA compared to the 
conservative PD of Geidobler et al. [13] indicated micro-collapse. In RN2-4 different temperature 
profiles, comparable to the considerations of CN2-4, were tested. The least aggressive RN2 
protocol resulted in a Tp of -14.2 °C, which was just the determined Tg` and a cake appearance, 
morphology, SSA and RM that was comparable to the lyophilizates processed by conservative 
PD. With RN3 and RN4 a Tp above Tg` (-14.7 °C) and below Tc (-10.1 °C), considering the 
measurement uncertainty of thermocouples, was reached (RN3: Tp=-12.8 °C; RN4: Tp=-
10.6 °C). However, the SSA of RN3 lyophilizates was slightly lower compared to RN4 
lyophilizates. In RN5-7, besides the hold time of Ts, also pc and the end point of Ts was changed. 
Although pc was reduced, the longer hold time at 20 °C led to a reduced SSA of RN5, 6, and 7 
products compared to the conservative PD lyophilizates of Geidobler et al. [13]. The aggressive 
PD RN lyo cycles resulted in RM values comparable or slightly lower to the conservative PD 
cycles. In contrast to the CN processes, it was possible to impact the resulting SSA of RN 
processes by the PD protocol. RN2 led to product specifications that completely met the target 
values defined by Geidobler et al. [13] and was therefore chosen as aggressive PD protocol for 
the RN process. Additionally, RN5 that resulted in an SSA between CN1 and RN2 was included 
into the mAb study to investigate the impact of this SSA reduction on reconstitution times.  
II.4.2 APPLICATION TO A MAB FORMULATION  
The mAb formulation was processed by the aggressive PD protocols of CN1, RN2, and RN5. 
Secondary drying was performed at 30 °C (0.1 °C/min) for 6 h. Comparable to the BSA 
formulation, PD time of all aggressive lyo cycles was remarkably shorter compared to the 
conservative PD protocol of Geidobler et al. [13]. Additionally, this reduction in PD time was 
independent of the nucleation protocol.  
Although Tp of CN1 and RN5 markedly exceeded Tc, no cake collapse was found. Microscopic 
analysis did not indicate micro collapse, a changed morphology or pore size, but in all three 
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cases a lower SSA compared to conservative lyophilizates of Geidobler et al. [13] was 
determined pointing to micro-collapse.  
Also, faster dissolution of the cakes was observed after aggressive PD. Furthermore, the 
positive effect of CN on reconstitution time, reported by Geidobler et al. [13], was noted. The 
lower SSA determined for RN5 BSA samples was not observed for the mAb formulation. 
Consequently, no impact on reconstitution behavior could be evaluated.  
The aggressive PD processes developed with a BSA formulation could successfully be applied 
to the mAb formulation without changing cake appearance, morphology or pore size, however, 
the processes were not optimized for the mAb formulation which resulted in different SSA.   
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II.5 CONCLUSION 
In this study, we showed that it is possible to combine controlled nucleation with aggressive 
primary drying for highly concentrated protein formulation without changing the product 
characteristics, cake appearance, morphology, pore size, SSA and RM. In case that CN is 
combined with an aggressive lyo cycle, PD time is remarkably reduced independent of the 
nucleation protocol. The positive effect of CN on reconstitution time was detected after both 
conservative and aggressive PD. Consequently, the potential of CN to improve other product 
quality attributes, e.g. mAb stability, should be evaluated next.  
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III.1 ABSTRACT 
This study provides the first systematic investigation of the impact of the nucleation protocol 
during freeze-drying on physico-chemical properties and long-term stability of two IgG1 
antibodies in sugar formulations. We hypothesized that the lower specific surface area (SSA) 
generated by controlled nucleation could be beneficial for the stability of interface sensitive 
proteins. The study compares controlled nucleated (CN) and randomly nucleated (RN) 
lyophilizates with high and low antibody concentrations stored at different temperatures. 
Formulations with and without polysorbate (PS) were included.  
In the “high concentration” study the formulation without PS showed reduced particle formation 
for CN samples compared to RN samples. PS containing formulations had an overall lower 
particle level with no further advantage of CN on stability. Besides the intended comparison of 
CN and RN samples, we observed that PS promoted sucrose crystallization in both low 
concentration antibody studies during storage. Additionally, our results indicate that the 
nucleation temperature (TN) was not the only determining factor for the resulting ice crystal size 
and consequently the product`s SSA. 
Overall, the application of CN had neither a positive nor a negative impact on the product`s 
physico-chemical stability. The surfactant had a much higher stabilizing effect than the reduction 
of the SSA by CN.  
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III.2 INTRODUCTION 
Freeze-drying is the method of choice for proteins that cannot be stabilized sufficiently in a liquid 
formulation. Freeze-drying comprises the freezing step, primary drying, and secondary drying 
and is a time consuming and expensive process. Therefore, researchers aim to reduce 
especially the long primary drying phase by increasing the sublimation rates [1-3]. Searle et al. 
[4] found that the ice nucleation temperature (TN) affects the primary drying rate and used TN as 
an indicator for ice crystal size. Higher TN resulted in higher primary drying rates and 
consequently shorter primary drying times [4]. An impact of TN on primary drying rate had been 
reported before by Roy and Pikal, who observed that vials containing thermocouples nucleated 
at higher temperatures and completed primary drying earlier [5].  
Recently, control over TN gained high interest in the field of freeze-drying. Various studies have 
been conducted to investigate the impact of TN on primary drying rate, specific surface area 
(SSA), and product resistance [6-11]. In a review, Geidobler and Winter [12] discuss the different 
technologies to induce ice nucleation and provide an overview of the difference in product 
characteristics, such as SSA and residual moisture (RM), between samples nucleated in a 
controlled way or randomly. Konstantinidis et al. [10] reported that higher TN causes a small 
number of large ice crystals, resulting in a lyophilized product with large pores and 
corresponding low SSA [6]. In contrast, at low TN a high number of small ice crystals is observed 
leading to a high SSA. On the one hand, the large pores of the controlled nucleated products 
reduce the product resistance and lead to a faster primary drying [4, 10]. On the other hand, 
during secondary drying, the low SSA hinders desorption leading to higher residual moisture 
levels [10], when secondary drying had not been adapted.  
The above-mentioned studies focused mainly on process parameters e.g. primary drying rate 
and product resistance; however, the change in SSA and the eventually higher residual moisture 
could also impact product quality. Geidobler et al. [13] applied controlled nucleation to highly 
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concentrated protein formulations and showed that besides reducing primary drying time, the 
resulting large pores could also improve reconstitution times of a highly concentrated 
monoclonal antibody (mAb) formulation. A further aspect of a reduced SSA is the smaller 
interface the protein is exposed to. As proteins are known to be sensitive to interfaces [14-18], 
theoretically, a lower SSA could be beneficial as the product is less exposed to degradation 
reactions. Previously, Schersch et al. [19-21] found that a low SSA generated by collapse can 
be beneficial for the stability of pharmaceutically relevant proteins (e.g. monoclonal antibody 
type IgG1, Actilyse®, lactate dehydrogenase). 
Although CN is getting more popular, there are only two published studies available on the 
influence of CN on protein stability. Awotwe-Otoo et al. [22] observed a lower degree of 
IgG1-glycation for lyophilizates with CN compared to RN. Recently, Fang et al. [23] correlated 
enzymatic activity and tetramer recovery of lactate dehydrogenase (LDH) with ice nucleation 
temperature. They found that at higher TN reduced LDH degradation after freeze-thaw and 
freeze-drying. However, the study did not consider storage of the formulations.  
Our study provides the first systematic investigation to evaluate the impact of the nucleation 
protocol, including TN, on the physico-chemical properties and importantly the long-term stability 
of lyophilizates of two IgG1 antibodies. We compared formulations processed by CN at high 
and low TN to samples processed by RN. Formulations at high and low concentration (76 or 
100 mg/ml vs 1 mg/ml) were compared to study the effect of a different ratio of protein to 
stabilizer on stability after lyophilization with different nucleation protocols. Non-ionic 
surfactants, e.g. PS 80 or 20 are commonly used to stabilize proteins against interface related 
stress by covering the interface at concentrations above the critical micelle concentration (CMC) 
[15, 24, 25]. Although a polysorbate-free formulation is likely not stable, the beneficial effect of 
CN may be more pronounced. Therefore, formulations with and without PS were tested in this 
study to evaluate the impact of a reduced SSA by CN in the presence and absence of a 
surfactant.  
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III.3 MATERIALS AND METHODS 
III.3.1 STUDY DESIGN 
Two studies, one with high protein concentration (76 or 100 mg/ml) and one with low protein 
concentration (1 mg/ml), both with 2 different antibodies, were designed (Figure III-1). A model 
IgG1 mAb without PS (mAb1) and a model IgG1 mAb with PS (mAb2) were investigated. Within 
the high concentration study, both antibodies were subjected to (i) CN at -5 °C and (ii) a RN 
freezing protocol. The primary and secondary drying protocol was the same in all cases. Within 
the low concentration study, an additional CN temperature at -10 °C, which is in the range of TN 
of the random nucleation process and the lowest achievable supercooling temperature allowing 
for CN before RN occurs, was included for mAb1. Thus, mAb1 was processed via (i) CN at -5 °C, 
(ii) CN at -10 °C, and (iii) RN. Furthermore, mAb1 was formulated with (+PS) or without 
polysorbate (-PS) to evaluate the influence of PS. MAb2 bulk drug substance solution already 
contained 0.04% polysorbate. Therefore, it was not possible to formulate mAb2 completely free 
of polysorbate. Instead, mAb2 was formulated with a nominal PS concentration of (i) 0.04% 
(+PS) and (ii) 0.0004% (dilution1:100), named as “without PS” (-PS). Based on the results of 
the at first performed mAb1 study, CN at -10 °C was not included in the mAb2 studies.  
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Figure III-1: Scheme of study designs for the high and low concentration study. * 0.04% PS 20. ° 0.04% PS 80. Δ 0.0004% 
PS 80; considered as “without polysorbate” (-PS). 
III.3.2 MATERIALS 
Two model monoclonal antibodies mAb1 and mAb2 (both IgG1) were used in this study. Di-
sodium hydrogen phosphate (AppliChem), sodium dihydrogen phosphate (AppliChem), and 
Ph.Eur. grade sucrose were purchased from VWR. PS 20 and PS 80 Ph.Eur. grade were 
purchased from Sigma-Aldrich. Low protein binding polyvinylidenfluorid (PVDF) and 
polyethersulfone (PES) 0.22 µm filters were purchased from Merck Millipore (Millipore, 
Schwalbach, Germany). 2R glass type I tubing vials were kindly provided by MGlas AG 
(Münnerstadt, Germany). Rubber stoppers, 13 mm (Westar® RS, 4023/50, bromobutyl, grey, 
FluoroTec B2-40 coating) were kindly supplied by West Pharmaceutical Services (Eschweiler, 
Germany). Further, standard aluminum crimp caps compatible with 13 mm stoppers were used. 
All vials and stoppers were washed manually three times with highly purified water (Milli-Q, 
Merck Millipore, Hertfordshire, United Kingdom). Vials were heat sterilized for at least 120 min 
High concentration
mAb1 
(76.6 mg/ml) 
(-PS)
CN -5°C Random
mAb2
(100 mg/ml) 
(+PS)
CN -5°C Random
Low concentration
mAb1 (1 mg/ml)
CN -5°C
-PS +PS*
CN -10°C
-PS +PS* 
Random
-PS +PS*
mAb2 (1 mg/ml)
CN -5°C
-PSΔ +PS°
Random
-PSΔ +PS°
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at 180 °C; stoppers were autoclaved at 121 °C for 20 min and dried at 80 °C not longer than 8 h 
after autoclaving. The stoppers were not re-dried prior to lyophilization.  
III.3.3 SAMPLE PREPARATION 
For the mAb1 high concentration study, mAb1 stock solution was first concentrated using a 
Minimate II Tangential Flow Filtration (TFF) system (Pall, Crailsheim, Germany) equipped with 
a 30 kDa TFF capsule (OmegaTM PES membrane). For the mAb1 low concentration study, the 
mAb1 stock solution was diluted with a 10 mM phosphate buffer (pH 6.4). The mAb2 stock 
solution was dialyzed against a 10 mM phosphate buffer (pH 6.4) containing 0.04% PS 20. 
Slide-A-Lyzer™ Dialysis Cassettes (10 kDa; 12-30 ml) (ThermoFisher Scientific, Ulm, 
Germany) were used and three buffer changes were performed (after 4 h, 6 h and overnight). 
The formulations were prepared according to the respective composition described in Table 
III-1.  
Table III-1: Overview of the composition of the formulations used in this study. 
 
Description 
 
Buffer system 
mAb 
concentration 
[mg/ml] 
 
Sucrose 
[mg/ml] 
 
Polysorbate 
80 [%] 
 
Polysorbate 
20 [%] 
mAb1 high 
concentration (-PS) 
10.5 mM 
phosphate  
pH 6.4 
 
76.6 
50 
 
0.00 ---- 
mAb1 low 
concentration (+PS) 
1.0 0.04 ---- 
mAb1 low 
concentration (-PS) 
1.0 0.00 ---- 
mAb2 high 
concentration (+PS) 
100.0 ---- 0.04 
mAb2 low 
concentration (+PS) 
1.0 ---- 0.04 
mAb2 low 
concentration (-PS) 
1.0 ---- 0.0004* 
 
Compounding was performed as follows: For mAb1, the target sucrose amount was dissolved 
in buffer before the antibody was then added. Subsequently, the formulation was filtered through 
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a 0.22 µm PVDF filter before the PS was added to the corresponding formulations. For mAb2, 
the polysorbate was added to the buffer with sucrose and mAb2 before filtering the formulations 
through a 0.22 µm PES membrane filter. To mitigate PS adsorption, the filter was pre-rinsed 
with PS and sucrose containing buffer. As we aimed to allow certain degradation, a low stabilizer 
concentration (50 mg/ml sucrose) was used resulting in a high protein to sugar ratio whereby 
the protein is likely more prone to instabilities. Additionally, a placebo formulation of each 
formulation was prepared. Sample aliquots of 1.0 ml were manually filled under laminar flow 
conditions and the vials were semi-stoppered manually. The formulations were lyophilized on 
the same day or the day after. 
III.3.4 LYOPHILIZATION 
Lyophilization was performed using an Epsilon 2-12D pilot scale freeze-dryer (Martin Christ, 
Osterode, Germany). The vacuum during the freeze-drying process was controlled by a 
capacitance (MKS) gauge. For product temperature monitoring and end of primary drying 
determination, thermocouples were used.  
By default, vials were backfilled to 600 mbar prior to stoppering. After completing backfill, the 
closed vials were stored at 5 °C until unloading. Subsequently, the vials were crimp capped with 
aluminum flip off caps. Deviation from this standard protocol will be stated in the affected 
sections. 
CN was performed by following the protocol described by Geidobler et al. [26]. To increase the 
amount of water vapor in the chamber, a tray with 1000 ml high-purified water was placed into 
the freeze-dryer. The vials were equilibrated for 2 h at the aimed nucleation temperature of -5 °C 
or -10 °C. After nucleation, the water tray was removed, and the shelf temperature was ramped 
to -50 °C at 1 °C/min. RN samples were equilibrated to 2 °C for at least 1 h before the shelf 
temperature was lowered to -50 °C at 1 °C/min. A hold time of 120 min at -50 °C was applied to 
all freezing protocols prior to initiating primary drying.  
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III.3.4.1 HIGH CONCENTRATION STUDIES DRYING PARAMETERS 
One CN and one RN freeze-drying cycle was performed. For both, primary drying was carried 
out at a shelf temperature of 0 °C (ramp rate: 0.5 °C/min) and a chamber pressure of 0.25 mbar. 
For secondary drying, the shelf temperature was raised to 30 °C for RN process and to 35 °C 
for CN process with a ramp of 0.1 °C/min and held for 6 h at unchanged pressure of 0.25 mbar.  
III.3.4.2 LOW CONCENTRATION STUDIES DRYING PARAMETERS 
One CN process and one combined process for RN and CN-10 was executed. For both, primary 
drying shelf temperature was set to -35 °C (ramp rate: 0.5 °C/min) and the chamber pressure 
to 0.02 mbar. Secondary drying was performed in two steps to allow adjustment of RM level 
between the different nucleation protocols. In a first step, the shelf temperature was raised to 
30 °C (with 0.1 °C/min to 5 °C and 0.2 °C/min to 30 °C). After a holding time of 6 h, the shelf 
temperature was raised to 40 °C (0.2 °C/min) and held for another 6 h. The CN samples, which 
have slower desorption rates, were subjected semi stoppered to both secondary drying steps, 
whereas the CN-10 and RN samples (faster desorption rates) were completely stoppered after 
the first secondary drying step (under full vacuum) and subjected to the additional secondary 
drying step only to assure equal thermal history. For comparability, CN-5 samples were also 
stoppered under full vacuum after both secondary drying steps.  
III.3.5 SAMPLING TIME POINTS AND STORAGE CONDITIONS 
Samples of the mAb1 high concentration study and the mAb2 studies were incubated at 40 °C 
and 75% relative humidity. Due to material constraints and the high material requirements, the 
high concentration studies were performed only under accelerated conditions. MAb1 high 
concentration samples were investigated over 12 months and analyzed after freeze-drying, 1, 
6, and 12 months upon storage. The mAb1 low concentration samples were stored at 
40 °C/75% r. H. and at 2-8 °C and analyzed after freeze-drying and after 3, 6, and 12 months 
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of storage. MAb2 high and low concentration samples were stored at 40 °C/75% r. H. and 
studied over 7 months and analyzed after freeze-drying, 3, and 6 months. Selected analytical 
characterization was additionally performed after 7 months of storage.  
III.3.6 DATA ANALYSIS AND ILLUSTRATION 
Throughout the manuscript, error bars represent the standard deviation (based on n = 3). If no 
error bars are shown, only one sample was analyzed due to material constraints.  
III.3.7 KARL FISCHER TITRATION (KF) 
The residual moisture of the lyophilized cakes was determined using the coulometric Karl 
Fischer titrator Aqua 40.00 (Analytik Jena GmbH, Jena, Germany), which is equipped with a 
headspace module. About 20 mg of sample was weighed into a 2R glass vial under a glovebox 
(r.h. ≤ 5%). The sample was analyzed at 150 °C. Prior to the measurements, a system suitability 
test was performed daily by measuring a pure water standard (Apura 1 water standard oven 
1.0, Merck KGaA). 
III.3.8 DIFFERENTIAL SCANNING CALORIMETRY (DSC) 
The glass transition temperatures Tg´ (of the frozen product) and Tg (of the lyophilized product) 
were determined by DSC (Mettler Toledo DSC1_943, Mettler Toledo, Giessen, Germany). 
Approximately 30 µl or 10 mg, respectively, of the product were transferred into an aluminum 
crucible (Mettler Toledo, Giessen, Germany). For Tg` determination, the samples were cooled 
to -80 °C with 10 K/min and re-heated to 20 °C with a heating rate of 10 K/min. For Tg 
determination, two heating cycles were performed. First, the samples were cooled to 0 °C with 
10 K/min and re-heated to 130 °C with a heating rate of 10 K/min. Second, the samples were 
re-heated to 160 °C after cooling to 0 °C. The midpoint of the endothermic shift of the baseline 
during the heating scan was taken as Tg` or Tg. For the high concentration studies, the 2nd 
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heating scan was considered, whereas for the low concentration studies the first heating scan 
was taken into account.  
III.3.9 X-RAY POWDER DIFFRACTION (XRD) 
The morphology of the lyophilized products was investigated by wide angle X-ray powder 
diffraction (XRD) (Empyrean; equipped with a copper anode (45 kV, 40 mA, Kα1 emission at a 
wavelength of 0.154 nm) and a PIXcel3D (Panalytical, Almelo, The Netherlands). Approximately 
100 mg of the freeze-dried samples were analyzed in reflection mode in the angular range from 
5-45° 2θ, with a step size of 0.05° 2θ and a counting time of 100 per step. 
III.3.10 BET ANALYSIS 
The SSA of the lyophilized material was analyzed by the BET method using an Autosorb-1 
(Quantachrome Instruments, Germany). For sample preparation, approximately 100 mg 
lyophilized sample was carefully crushed with a spatula into small pieces and filled in a 
measurement tube. Degassing was performed for at least 2 h at 25 °C. Subsequently, Krypton 
sorption measurement was performed at 77.3 K. At least 5 data points were collected covering 
a p/p0 region of 0.05 to 0.3. The data points were evaluated according to the multipoint BET-
method with r ≥ 0.997 for all samples. 
III.3.11 RECONSTITUTION PROCEDURE AND DETERMINATION OF 
RECONSTITUTION TIME 
The lyophilized products were reconstituted under laminar flow conditions. The required volume 
for reconstitution was calculated for each formulation based on the density of the liquid 
formulation and the total solid content. The desired amount of highly purified water was added 
to the center of the lyophilized product. The vial was carefully slewed. The time until complete 
reconstitution was recorded as reconstitution time.   
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III.3.12 MICRO-FLOW IMAGING (MFI) 
MFI was chosen to determine micrometer-sized particles as it provides more information on 
particle`s morphology based on images, compared to the compendial required light obscuration 
method. Furthermore, MFI requires less sample volume, which was a limiting factor in our study. 
An MFI-5200 particle analyzer system (ProteinSimple, Santa Clara, CA, USA) equipped with a 
silane coated high-resolution 100 µm flow cell and controlled by MFI View software was used. 
The system was flushed with at least 3 ml highly purified water at maximum flow rate prior to 
each measurement. Corresponding placebo buffers were used to perform “optimize 
illumination” after the cell cleanliness was checked before each measurement. The samples of 
the high concentration studies were diluted to 1 mg/ml with the corresponding placebo buffer. 
For the mAb1 high concentration samples (0.75 ml), a purge volume of 0.3 ml was set, and 
0.33 ml of the samples were analyzed. For all other samples (0.65 ml) a purge volume of 0.17 ml 
was used, and 0.28 ml were analyzed. All samples were pipetted using filter tips. MFI View 
System Software (MVSS) version 2-R2-6.1.20.1915 was used to perform the measurements 
and MFI View Analysis Suite (MVAS) software version 1.3.0.1007 was used to analyze the 
samples. 
III.3.13 DYNAMIC LIGHT SCATTERING (DLS) 
DLS was used to measure the size and size distribution of particles in the submicron region 
(1 nm-1 µm). Measurements were conducted using a Zetasizer APS 2000 plate reader (Malvern 
Instruments, Worcestershire, UK) instrument. Three wells (n=3, each with 150 µl of the sample) 
were analyzed using automatic measurement mode at 20°C at an angle of 90°. All samples 
were pipetted under laminar flow. MAb1 samples (high and low concentration study) were 
analyzed without dilution. Samples of the mAb2 high concentration study were diluted (w/w) to 
1 mg/ml. The Malvern Zetasizer Software was used to fit the autocorrelation function using the 
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default settings for protein solutions and to calculate z-average diameter, polydispersity index 
(PDI), and particle size distribution by intensity. 
III.3.14 HIGH PERFORMANCE SIZE EXCLUSION CHROMATOGRAPHY (HP-
SEC) 
Protein monomer, dimer, fragments, and high molecular weight soluble aggregates were 
determined by HP-SEC (HP 1100, Agilent Technology). All separations were performed using 
a TSKgel G3000 SWXL column (Tosoh Bioscience, Stuttgart, Germany) at a flow rate of 
0.5 ml/min with a sample loading of 20 µg and UV detection at 280 nm. A 50 mM sodium 
phosphate buffer with 300 mM sodium chloride at pH 7.0 was used as mobile phase. Prior to 
analysis, the samples of the high concentration studies were diluted to 1 mg/ml with formulation 
buffer.  
III.3.15 SODIUM DODECYL SULFATE-POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE) 
Covalent aggregates and fragments of mAb2 low concentration study samples were assessed 
using reducing and non-reducing SDS-PAGE. Analysis was performed with a XCell SureLockTM 
Mini-Cell Electrophoresis System (Novex® by Life Technologies, Carlsbad, CA, USA). For 
reducing conditions, a NuPAGE® Novex® 4-12% Bis-Tris Protein Gel with NuPAGE® MES SDS 
Running Buffer (200 V for approximately 35 min) was used. Non-reducing conditions analysis 
was accomplished using a NuPAGE® Novex® 3-8% Tris-Acetate Protein Gel with NuPAGE® 
Tris-Acetate SDS Running Buffer (150 V for approximately 55 min). For reducing conditions, 
80 µl sample at 100 µg/ml was admixed with 40 µl NuPAGE® LDS Sample Buffer, 16 µl of 
NuPAGE® Reducing Agent and 24 µl of the corresponding placebo buffer (final concentration 
of 50 µg/ml). For non-reducing conditions, the 16 µl of reducing agent were replaced by placebo 
buffer. All samples were denatured at 90 °C for 5 min. Each well was loaded with 12 µl sample 
which resulted in a total mass of 0.6 µg protein per well. Gels were stained with a SilverQuestTM 
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Staining Kit (Invitrogen® by Life Technologies) according to supplier’s instructions. To assess 
size of protein bands, Molecular weight markers were added on each gel. For reducing 
conditions, Mark12™ Unstained Standard and for non-reducing conditions HiMark™ Pre-
stained Protein Standard (both from Invitrogen® by Life Technologies) was applied. SDS-PAGE 
gels were scanned with a GS-800 densitometer (BioRad Laboratories, Hercules, CA, USA). 
  
DOES CONTROLLED NUCLEATION IMPACT THE PROPERTIES AND STABILITY OF LYOPHILIZED 
MONOCLONAL ANTIBODY FORMULATIONS? 
53 
III.4 RESULTS  
III.4.1 HIGH CONCENTRATION STUDY 
CHARACTERISTICS OF THE LYOPHILIZATES 
First, product appearance was compared. After freeze-drying, mAb1 and mAb2 RN cakes 
showed a white to yellowish, compact, appearance with a shiny surface, minor shrinkage in 
height, and tiny cracks. The structure of CN cakes was more porous, loose, and shiny. 
Comparable shrinkage in height was observed for RN and CN samples, however crack 
formation was more pronounced in CN samples. During storage, minor loss in cake structure 
was observed for RN and CN samples similarly (Photographs provided in APPENDIX Figure 
VIII-3). 
Next, the freeze-dried product´s RM content, morphology, and glass transition temperature was 
analyzed. Immediately after freeze-drying the RM were below 1% for all samples (APPENDIX 
Figure III-2). As expected, the CN samples had higher RM content as the RN samples after 
freeze-drying in mAb1 and mAb2 study. During storage, RM increased in parallel for CN and 
RN samples. DSC results were in line with the KF results. After freeze-drying, overall high Tg 
values, 75 °C for mAb1 CN and 79 °C for mAb1 RN samples, were determined (APPENDIX 
Figure VIII-4). The higher RM of the CN samples resulted in an initially lower Tg compared to 
RN. Upon storage, the Tg values decreased in all cases. XRD showed that the samples were 
fully amorphous without crystallization during storage (APPENDIX Figure VIII-5).  
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Figure III-2: RM content of CN and RN samples of (A) mAb1 and (B) mAb2 high concentration study over storage time at 
40°C/75% r.h.. 
The results of the SSA measurements confirmed the successful performance of CN because 
after freeze-drying, a lower SSA was observed for CN samples compared to RN samples for 
both mAb studies (Figure III-3). Over 6 months storage time, a decrease in SSA by 16% for 
mAb1 CN samples and of 33% for mAb1 RN samples was noted. The same tendency was 
observed for mAb2 (CN samples decreased by 24%; RN samples by 38%). 
 
Figure III-3: SSA of CN and RN samples of (A) mAb1 and (B) mAb2 high concentration study over storage at 40°C/75% r.h.. 
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MAB STABILITY 
No difference in the relative content of monomer and higher molecular weight species (HMW) 
determined by HP-SEC was observed when comparing CN and RN within one study (Figure 
III-4). During the stability study, both antibodies showed an increase in HMW content and 
aggregate formation in mAb1 samples was more pronounced than in mAb2 samples. 
 
Figure III-4: Monomer and HMW relative content for mAb1 (A) and mAb2 (B) over storage at 40°C/75% r.h. (standard 
deviations below resolution; n=3). 
MFI was used to quantify particles in the micrometer size range. After freeze-drying, comparable 
particle counts were measured for mAb1 CN and RN samples. During storage, mAb1 CN 
samples showed less particle formation in the micrometer size range compared to the RN 
samples (Figure III-5A). For mAb2, no difference between the samples generated by the 
different nucleation protocols could be detected after freeze-drying and upon storage (Figure 
III-5B).  
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Figure III-5: Cumulative particle counts of particles ≥ 1 µm for (A) mAb1 and (B) mAb2 over storage at 40°C/75% r.h.. Please 
note that the y-axis is scaled differently in A and B to achieve better resolution.  
Additionally, the particle size distribution in the nm-size range was measured by DLS. For mAb1, 
a difference in z-average between CN and RN samples was observed. After lyophilization (T0), 
a z-average of ~ 10 nm was measured for both formulations, which is expected for a mAb. MAb1 
CN samples show less increase in z-average values over storage than corresponding RN 
samples (Figure III-6A). Further, the size distribution for mAb1 CN samples showed a lower 
level of aggregates with increasing storage time compared to the RN samples (APPENDIX Figure 
VIII-6A and B). For the mAb2 study, no difference between the CN and RN samples regarding 
z-average values and size distribution was identified (Figure III-6B, APPENDIX Figure VIII-6C 
and D). 
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Figure III-6: z-average of CN and RN samples of (A) mAb1 and (B) mAb2 high concentration study over storage at 40°C/75% 
r.h..   
III.4.2 LOW CONCENTRATION STUDY 
STORAGE AT 5°C (MAB1) 
The analysis of the freeze-dried products of the mAb1 samples stored at 5 °C did not show any 
change over a storage time of 12 months. Tg, RM and XRD refractograms of T12m were 
comparable to T0 for both nucleation protocols. No change in monomer content over 12 months 
of storage was recognized. However, a minor increase in micrometer sized particles in both 
nucleation protocols of formulations without PS was observed compared to T0. Formulations 
with PS were comparable to T0. As these results did not indicate any difference between CN 
and RN samples and the changes over time are minor, the 5°C data are not discussed further.  
STORAGE AT 40°C/75% R.H. (MAB1 AND 2) 
CHARACTERISTICS OF THE LYOPHILIZATES 
MAb1 RN samples showed a white, compact, cylindrical cake with a shiny surface, minor 
shrinkage in height, and tiny cracks. The structure of mAb1 CN-5 cakes was more porous, loose 
and shiny. Shrinkage in height and crack formation was more pronounced in mAb1 CN-5 
samples compared to RN samples. The cake structure of mAb1 CN-10 samples was more 
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comparable to CN-5 samples than to RN samples. However, the level of shrinkage in height 
and crack formation ranged between the CN-5 and RN samples of mAb1. After 3 months of 
storage at 40 °C/75% r.h., no change in optical appearance was determined for any of the mAb1 
samples (all nucleation protocols). At 6 months’ time point mAb1 CN-5 and CN-10 samples 
showed a loss in cake structure and began to collapse. The degree of collapse was higher in 
CN-10 samples, which had a higher residual moisture (see below). For mAb1 RN samples, no 
change was documented. After 12 months of storage at 40 °C/75% r.h., collapse was observed 
in all mAb1 samples (Photographs provided in APPENDIX Figure VIII-7).  
For mAb2, the differences in cake structure between CN-5 and RN samples were less 
pronounced. The change in cake appearance over storage time (40 °C/75% r.h.) was 
comparable to mAb1 with no change up to 3 months and beginning collapse at 6 months. In 
contrast to mAb1, mAb2 RN samples collapsed to the same degree as CN-5 samples. As for 
mAb1, no difference between the formulation with and without PS was determined 
(Photographs provided in APPENDIX Figure VIII-7).  
Next, the freeze-dried product was analyzed by KF titration, SSA measurement, XRD and DSC. 
At T0, immediately after freeze-drying, all formulations of mAb1 and mAb2 showed RM below 
1% (Figure III-7). The alignment of the RM content to a similar level between the CN and RN 
samples by two secondary drying steps was successful for the CN-5 and RN samples. The 
samples of mAb1 nucleated at CN-10 were expected to show drying properties comparable to 
RN samples due to the comparable low TN. Therefore, the mAb1 CN-10 samples had been 
subjected to the same secondary drying protocol as the RN samples. However, the drying 
behavior differed from the RN samples, thus, the CN-10 samples of mAb1 showed higher RM 
(Figure III-7A). An increase in RM over storage time was observed for all samples of both 
antibodies (Figure III-7A and B). After 6 months of storage, no differences between the 
nucleation protocols and the formulations with and without PS were observed.  
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Figure III-7: Residual moisture content of CN and RN samples of low concentration study over storage time. (A) mAb1 and 
(B) mAb2. After 12 months, analysis via KF titration was not possible for the collapsed samples. 
SSA measurements confirmed the explanation for the higher RM of mAb1 CN-10 samples. 
Although CN-10 samples were nucleated at a low TN, their SSA and consequently their drying 
behavior was comparable to the samples controlled nucleated at -5 °C (Figure III-8A) and not 
to the randomly nucleated samples. In both mAb studies, for all CN samples a lower SSA was 
determined compared to the RN samples (Figure III-8). Thus, CN was successfully performed. 
With increasing storage time, a loss in cake structure based on both appearance and SSA was 
observed. For mAb1 RN samples a loss in SSA of about 15% was determined, whereas for 
mAb1 CN-5 and CN-10 samples a loss of about 40% was noted. For mAb2, SSA decreased 
comparably in CN and RN samples. Additionally, no difference between formulations with and 
without PS could be identified.  
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Figure III-8: Results of SSA measurements of CN and RN samples over storage time. (A) mAb1 and (B) mAb2 low 
concentration study. After 12 months, analysis via BET was not possible for the collapsed samples. 
XRD measurements pointed towards an amorphous structure of all formulations after 
freeze-drying (Figure III-9). Formulations without PS did not change morphology during storage. 
Surprisingly, PS provoked sucrose crystallization within the lyophilized formulations during 
storage. After 12 months of mAb1 storage and after 7 months of mAb2 storage, respectively, 
sucrose crystallization was observed only in the PS containing formulations, independent of the 
nucleation protocols in both antibody studies. 
The above observed increase in RM during storage resulted in a decrease of Tg measured by 
DSC (APPENDIX Figure VIII-8). Comparable to the RM results, no differences between the 
nucleation protocols could be detected. The DSC thermograms confirmed sucrose 
crystallization provoked by PS, which agrees with XRD. Figure III-10 displays examples of 
thermograms of CN-5 and RN (-PS/+PS) samples of mAb1 and mAb2. Sucrose crystallization 
during storage was only observed in PS containing formulations, when no Tg could be measured 
anymore (Figure III-10: right column). 
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Figure III-9: XRD-refractograms of all nucleation protocols of mAb1 (top row) and mAb2 (bottom row) of the formulations 
without PS (left column) and the formulations containing PS (right column). For mAb1 the results at T0, T6m and T12m 
are exemplarily shown. For mAb2 XRD measurements were performed only at T7m to confirm DSC results.  
The peak, observed at temperatures ≥ 70 °C, appears due to sucrose degradation at elevated 
temperatures and does not indicate the sample morphology (amorphous or crystalline) upon 
storage. (Figure III-10: top row, right column, CN-5 is provided as example). Sucrose 
crystallization in PS containing samples of mAb2 was first observed for the CN-5 samples after 
T6m, and slightly later for mAb2 RN samples (between 6 months and 7 months of storage). For 
the mAb2 RN samples, a Tg was determined at T6m, indicating an amorphous structure (Figure 
III-10: bottom row, right column), whereas at T7m no Tg could be detected anymore (pointing 
towards sucrose crystallization).  
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Figure III-10: Examples of DSC thermograms of controlled nucleated and random nucleated samples of mAb1 at T0, after 
6 months (T6m) and 12 months (T12m) of storage and mAb2 at T0, after 6 months (T6m) and 7 months (T7m) of storage. 
The graphs of the left column display the formulations without PS, whereas the graphs in the right column show the 
corresponding formulations with PS.  
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MAB STABILITY  
HP-SEC was used to study protein aggregation and fragmentation. Additionally, nanometer and 
micrometer range particles of all reconstituted samples were assessed by DLS or MFI, 
respectively. The HP-SEC results for mAb1 did neither show aggregation nor fragmentation of 
mAb1 independent of the nucleation protocol (Figure III-11A and B). For mAb2 CN-5/+PS 
samples, a decrease in monomer content and a corresponding increase in HMW species at 
T6m was detected (Figure III-11C and D). The mAb2 RN/+PS samples showed the same trend 
at T7m. A slight increase in fragments was determined for both nucleation protocols at T7m. 
The corresponding formulations without PS did not show any change in monomer content, HMW 
or fragments over a total storage time of 7 months. The increase in HMW was observed at the 
same time points as the sucrose crystallization.  
 
Figure III-11: (A) Monomer content of mAb1, (B) HMW species content of mAb1, (C) monomer content of mAb2 and (D) 
HMW species content of mAb2, measured by HP-SEC.  
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For mAb2 samples, reducing and non-reducing SDS-PAGE was performed to further 
characterize the HMW species observed in HP-SEC. The observed aggregation in SDS-PAGE 
was more pronounced in mAb2 CN-5/+PS than in the mAb2 RN/+PS samples at T7m. From 
SDS-PAGE under reducing conditions, it could be proven that the aggregates were S-S-linked 
(APPENDIX Figure VIII-9and Figure VIII-10). 
Both, DLS and MFI data did not indicate a difference with respect to nanometer and micrometer 
range particle formation between the nucleation protocols after freeze-drying and upon storage 
in both antibody studies (APPENDIX Figure VIII-11 and Figure VIII-12). Independent from the 
nucleation protocol, lower particle numbers were observed for the PS containing formulations. 
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III.5 DISCUSSION 
Our study provides a systematic investigation on the impact of CN protocols (including TN) on 
long-term stability of pharmaceutically relevant IgG1 formulations over a storage time of at least 
6 months. We hypothesized that the lower SSA generated by CN at higher TN could be 
beneficial for the stability of proteins, which are sensitive to interfaces. We investigated this 
hypothesis by a high concentration and a low concentration mAb study. Furthermore, as the 
relevance of a potential surface exposure and other stresses could be diminished by the 
surfactant effect, formulations with and without PS were compared.  
First, the results of the high concentration study will be discussed. Then, a discussion of the 
results of the low concentration study including a comparison of both studies will follow. Details 
of the freeze-drying processes and primary drying times are provided as supplementary material 
(APPENDIX Figure VIII-13, Figure VIII-14, Table VIII-1), as the optimization of the drying time was 
not focus of this study. As expected, CN processes resulted in either a faster primary drying or 
CN and RN processes did not differ [4, 6, 10]. 
We noted a difference in cake appearance between the CN and RN samples for both antibodies 
at both concentrations. Overall, cake appearance can be considered as pharmaceutically 
acceptable for both CN and RN, with the cakes from RN having a more elegant appearance. As 
such an optical difference has been reported before by Awotwe-Otoo et al. [27], our results 
confirm the literature and were not surprising. A recently published commentary by Patel et al. 
[28] on cake appearance suggests judging product quality mainly with respect to patient safety. 
Transferring this perspective to our study, the different appearance of CN samples can be 
accepted as we did not observe a negative effect of CN on protein stability.  
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III.5.1 HIGH CONCENTRATION STUDIES 
We expected a higher RM for CN samples due to the lower SSA and the therefore slower 
desorption rate during secondary drying [6, 10] as, in contrast to the low concentration study, 
the secondary drying process was not adjusted. At T0, CN and RN samples have RMs of less 
than 1% and are therefore considered as well dried. However, based on the higher RM of CN 
samples, a higher level of SSA loss over storage time would have been expected for CN 
samples, while we observed a faster decrease of SSA in RN samples. Additionally, DSC and 
XRD data did not indicate any effect (e.g. excipient crystallization) due to the higher RM content 
of the CN samples. This observation holds true for both antibodies.  
For mAb 1 without surfactant (-PS), less particle formation (nanometer and micrometer sized 
range) was found for CN samples compared to RN samples, which confirms our hypothesis that 
a reduced surface/interface prevents proteins from surface induced instabilities. For mAb2 with 
surfactant (+PS), no differences between CN and RN samples were determined. Thus, the 
surfactant concentration was sufficient to protect CN and RN processed proteins equally. The 
presence of PS outweighed the differences based on nucleation protocols. Consequently, CN 
nucleation and the resulting low SSA did not lead to additional benefits with respect to the 
stability of a highly concentrated IgG1 formulation if a surfactant is present in the formulation. 
Additionally, the relative monomer content decreased comparably in both nucleation protocols 
over storage time and did not indicate stability improvements by CN for both antibodies.  
III.5.2 LOW CONCENTRATION STUDIES 
A difference between the residual moisture of CN and RN samples could be eliminated without 
changing the thermal history of the samples by introducing a further secondary drying step at 
higher temperatures. CN-10 samples were treated comparably to RN samples, because for both 
a fast desorption was assumed (= low nucleation temperature). However, against our 
assumption, CN-10 samples resulted in physical properties comparable to CN-5 samples. Thus, 
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CN itself and not TN was the determining factor. Further, we suppose that CN at different TN 
results in rather similar product characteristics.  
In contrast to the high concentration study, no difference with respect to particle formation 
between the CN and RN samples was detected; neither for the formulations without surfactant 
(-PS) nor for the formulations with surfactants (+PS) for both antibodies. However, as expected, 
+PS formulations showed clearly reduced particle numbers compared to the corresponding -PS 
formulations. From theory, the percentage of protein in contact with an interface/surface is 
higher in samples of a low protein concentration compared to samples with a high protein 
concentration. Thus, it was expected that the potential positive effect of CN on particle formation 
would be more pronounced in the low concentration study. However, this was not the case, as 
we did not detect any difference between CN and RN samples. HP-SEC data supported the 
comparability of both nucleation protocols. Even though, the decrease of monomer content of 
mAb2 RN samples occurred time-delayed, the decrease was determined in CN and RN samples 
by HP-SEC and confirmed by SDS-PAGE.  
Additionally, we observed that PS20 and PS80 surprisingly promoted sucrose crystallization in 
both antibody studies during storage at 40°C/75% r.h.. The phenomenon of sucrose 
crystallization in lyophilizates stored at elevated temperatures is well-known in literature, but to 
our knowledge, the promotion of this crystallization by PS has not been reported before. Further, 
it is well-known that excipient crystallization can cause aggregation, structural loss, and loss of 
activity as the glassy matrix stabilizing the protein by forming hydrogen bonds is lost [29-31]. 
This was also observed in our study, as with the crystallization of sucrose, the monomer content 
of mAb2, measured by HP-SEC, decreased significantly.  
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III.6 CONCLUSION 
This systematic study pointed out three remarkable findings. First, CN applied during the 
freezing step of a freeze-drying cycle did neither improve mAb stability nor negatively affect 
stability. These conclusions are based on a large dataset with two different antibodies, studied 
at two different concentrations (low and high) in typical formulations with and without surfactant. 
Second, in this study, the CN protocol and not TN determined the SSA and cake appearance. 
This hypothesis will be investigated further in a separate study. Third, the notable impact of PS 
on the crystallization of sucrose in lyophilizates stored at elevated temperatures has been 
demonstrated for the first time. 
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IV.1 ABSTRACT 
Improving freeze-drying processes regarding drying time and batch homogeneity is subject of 
ongoing research work. In this context, controlled nucleation raised great expectations. 
However, practically we face some challenges, e.g. how to non-destructively monitor 
successfully performed controlled nucleation. The question if different controlled nucleation 
methods lead to comparable products, as not every method can easily be implemented in lab 
and production scale equipment, is also of high interest. Additionally, the optimal nucleation 
temperature for controlled nucleation is an open question. In our study, we addressed these 
challenges. We successfully evaluated frequency modulated spectroscopy as a fast and 
non-destructive method to monitor controlled nucleation success and batch homogeneity. We 
found that the better homogeneity generated by controlled nucleation during the freezing step 
did not sustain in the dried product. Lyophilizates produced by three different ice fog methods 
for controlled nucleation were characterized by comparable specific surface areas but differed 
in residual moisture content. To investigate the impact of TN on the resulting specific surface 
area, we performed CN at -3 °C and -10 °C. We concluded that TN is not the only specific 
surface area determining factor and a high TN does not necessarily lead to larger pores but 
poses a higher risk of not-nucleating vials. 
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IV.2 INTRODUCTION 
One important aspect in lyophilization process development is the optimization of the primary 
drying time by adjusting shelf temperature and chamber pressure to increase sublimation rate 
[1-6]. Since Searles et al. [4] identified the ice nucleation temperature (TN) as a relevant factor 
for the primary drying rate during lyophilization, the freezing step gained in importance for 
freeze-drying cycle optimization. A higher TN generally results in larger ice crystals; and with 
these larger pores during sublimation, product resistance is reduced and thus, primary drying 
time shortened [4, 7, 8]. Moreover, larger pores (generated at higher TN) reduce the specific 
surface area (SSA), which induces slower desorption rates during secondary drying and thus 
can cause higher residual moisture (RM) levels of the final product if secondary drying is not 
modified when compared to the step utilized in a process where ice nucleation was not 
controlled [7, 9].  
Lyophilization cycle control, scale-up and transfer are important steps in product development 
and large-scale production. The stochastic nature of TN and its dependency on process and 
formulation variables may induce heterogeneity from vial to vial within a batch. TN is typically 
higher in a development environment where more particles can be introduced into the vials that 
function as nucleation sites. For successful process transfer, it needs to be considered that the 
vials tend to nucleate at lower TN during production due to the almost particle free environment. 
This can result in longer primary drying times than expected based on the experience from 
process development. Therefore, it is of major interest to control TN in order to control product 
resistance, drying times and (indirectly, as a result of cake resistance) Tp [7, 9, 10], and 
additionally, to reduce vial to vial heterogeneity [10-12]. However, it needs to be considered that 
differences in the heat transfer, e.g. edge vial effects or temperature inhomogeneity of the shelf, 
could also cause vial to vial heterogeneity within a batch [6, 13-17]. In our study, we did not 
focus on those heat transfer differences across a batch. They are well known and occur in 
different freeze-dryers to a different extent. We wanted to investigate if it is possible to improve 
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the vial to vial homogeneity of a batch although the heat transfer might be different across the 
shelf. If the heat transfer differences overcome the homogeneity generated by CN, the 
application of CN does not enhance product quality and uniformity.  
Geidobler and Winter [18] summarized the different approaches to induce ice nucleation that 
lead to the development of today’s commercial methods. Ice fog and pressure change methods 
are the two key techniques to induce ice nucleation and thus control TN. Commercially available 
ice fog methods are, e.g. FreezeBooster® (Millrock Technology), LyoCoN (Martin Christ), and 
VERISEQ® nucleation system (IMA life/Linde). ControLyoTM (SP Scientific), SynchroFreeze 
(Hof) and a recently published method from OPTIMA pharma [19] represent three methods 
based on pressure change.  
For the claimed benefits of controlled nucleation (CN), in particular improved batch 
homogeneity, it is crucial that the applied methods result in CN of 100% of all vials of a batch. 
Furthermore, as CN at higher TN results in lower SSA and a higher RM compared to random 
nucleation (RN) [7, 9], a non-destructive method to distinguish between controlled nucleated 
and not-controlled nucleated vials is needed. Currently, non-destructive approaches to monitor 
successfully performed CN are lacking. It is furthermore an open question, if it is necessary to 
apply the same CN method in development and production scale to achieve comparable product 
properties. In a recently published study, Gitter et al. [20] compared two mechanistically different 
methods to induce controlled nucleation, ice fog and depressurization, regarding nucleation 
behavior, process length and properties of the resulting lyophilizates. They exhibited that both 
techniques led to comparable process performance and product quality attributes.  
Additional effects of CN that have been reported are the reduction of reconstitution time for 
highly concentrated protein formulations [21], and the impact of CN on the degree of protein 
glycation [22] as well as enzyme activity (lactate dehydrogenase) [23]. In a previous work, we 
found that CN did neither have a positive nor a negative effect on the stability of an IgG1. 
Additionally, we observed that for the used mAb formulation, also the application of CN versus 
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RN and not primarily TN determined the resulting SSA [24]. Thus, it needs to be investigated if 
the morphology of the seeding crystals or the formulation composition, besides TN, defines the 
ice crystal morphology and thus product resistance, primary drying time and the product`s SSA.  
In this study we evaluated frequency modulated spectroscopy (FMS) as a tool to 
non-destructively monitor successful performance of CN. FMS determines the water activity as 
a surrogate parameter for RM at high throughput. RM is considered as a key quality attribute 
for lyophilizates and is known to alter if CN is applied. Therefore, we generated a CN batch with 
a certain percentage (~10%) of randomly nucleated vials by using a non-optimized controlled 
nucleation protocol. The 100% control of the batch by FMS also enabled us to study batch 
homogeneity.  
The product properties optical appearance, microscopic cake structure, SSA and RM, and the 
process times of lyophilizates generated by three different ice fog methods, namely 
FreezeBooster® (Millrock Technology), VERISEQ® nucleation system (IMA life/Linde), and the 
method described by Geidobler et al. [25], were compared to address the question if different 
nucleation methods result in comparable product properties. These three methods differ in ice 
fog generation temperature and induction pressure, which suggests a different morphology of 
nucleation seeds (e.g. hexagonal, dendritic, and dispersed spherulitic) and thus texture of the 
and texture of the ice fog.  
The ice fog method described by Geidobler et al [25], generates an in-situ ice fog in the chamber 
by releasing the previously applied vacuum of ~ 3.7 mbar through the cold condenser 
(approximately -70 °C). During the FreezeBooster® method, the chamber was evacuated to 
66 mbar (50 Torr) and prior to nucleation induction, the condenser was loaded with nucleation 
seeds by spraying water steam into the -80 °C cold condenser [26]. This generated a snow-
flake like ice fog. As third method the VERISEQ® nucleation system was used. Here, liquid 
nitrogen is combined with water vapor to generate a very fine ice fog dispersion. For ice fog 
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injection, the chamber pressure is reduced to 275 mbar [27]. All methods could be optimized 
with respect to 100% CN success by modifying the vacuum used for injection. 
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IV.3 MATERIALS AND METHODS 
IV.3.1 STUDY DESIGN 
Three ice fog methods, the VERISEQ® nucleation system, the Millrock FreezeBooster® and the 
method published by Geidobler et al., were compared (Figure IV-1). Each method was applied 
at two different TN, -3 °C and -10 °C, to investigate the impact of TN on SSA when CN is applied. 
A TN of -3 °C was the highest possible TN that resulted in acceptable nucleation success. A TN 
of -10 °C was chosen as it is within the range of RN nucleation temperatures where the risk of 
spontaneous random nucleation is low. As the VERISEQ® nucleation system was attached to a 
Christ Epsilon 2-12D freeze-dryer, whereas the Millrock FreezeBooster® and the method by 
Geidobler et al. were performed on a Millrock Magnum freeze-dryer, two random nucleation 
protocols, applied on both freeze-dryers, were used to account for freeze-dryer differences. In 
one random protocol, the vials were equilibrated to 2 °C, and in the other, the vials were 
equilibrated to -3 °C, comparable to the CN-3°C nucleation protocol. To investigate the impact 
of formulation composition, all experiments were performed with a sucrose-based (F1) and a 
trehalose-based (F2) formulation of a monoclonal antibody (mAb; final concentration 10 mg/ml 
(Table IV-1). Additionally, the impact of protein concentration on SSA was investigated. 
Therefore, three additional mAb concentrations, 1, 50, and 100 mg/ml (F3, F4, F5, respectively; 
all sucrose-based), were studied with the method published by Geidobler et al.  
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Figure IV-1: Study design 
IV.3.2 MATERIALS 
A monoclonal antibody (mAb), IgG1, was used in this study. Ph. Eur. grade sucrose, trehalose, 
and polysorbate 20 were purchased from Sigma-Aldrich; di-Sodium hydrogen phosphate 
(AppliChem), sodium dihydrogen phosphate (AppliChem) were purchased from VWR. Low 
protein binding polyvinylidene fluoride (PVDF) filters (0.22 µm) were purchased from Merck 
Millipore (Millipore, Schwalbach, Germany). 
6R glass type I tubing vials were purchased from Schott AG (Mainz, Germany). Stoppers 
(Westar® RtS, 20 mm, Silicone A) and flip off caps were supplied by West Pharmaceutical 
Services (Eschweiler, Germany). All vials and stoppers were washed with highly purified water 
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(Milli-Q, Merck Millipore, Hertfordshire, United Kingdom) and heat sterilized or autoclaved and 
dried, respectively. 
IV.3.3 FORMULATION PREPARATION 
After complete thawing (2-8°C) and mixing of mAb bulk solution, each formulation was prepared 
and lyophilized latest 24 h after preparation. The formulations were prepared according to the 
respective composition described in Table IV-1. Prior to filling, all formulations were filtered 
through a 0.22 µm PVDF membrane filter.  
Table IV-1: Overview of the composition of the formulations used in this study. 
Description Buffer 
system 
mAb 
concentration 
[mg/ml] 
Sucrose 
[mg/ml] 
Trehalose 
[mg/ml] 
Polysorbate 
20 [%] 
F1 
10.5 mM 
phosphate  
pH 6.4 
 
10.0 
75 
 
----- 0.04 
F2 10.0 ----- 75 0.04 
F3 1.0 75  0.04 
F4 50.0 75  0.04 
F5 100.0 75  0.04 
 
Aliquots of 2.5 ml were manually filled per vial under laminar flow and the vials were semi-
stoppered. In total 20 vials of each formulation were prepared and placed in the center of the 
shelf.  
IV.3.4 LYOPHILIZATION 
Lyophilization was performed by using an Epsilon 2-12D pilot scale freeze-dryer (Martin Christ, 
Osterode, Germany) or a Millrock Magnum pilot scale freeze-dryer (Millrock Technology Inc., 
Kingston, NY, USA). The vacuum during the freeze-drying process was controlled by a Pirani 
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gauge or an MKS capacitance manometer depending on the technical capabilities of the 
freeze-dryers. Tp and end of primary drying was determined by thermocouples. Table IV-2 
provides an overview over the performed freeze-drying cycles and presents the technical setup 
for each cycle. 
Before CN, the vials were equilibrated for at least 3 h to the desired TN prior to induction of 
nucleation. Immediately after CN, solidification was achieved by reducing the shelf temperature 
at 1 °C/min to -50 °C in all cases. For random nucleation, the vials were equilibrated (i) at 2 °C 
and (ii) at -3 °C for at least 3 h prior to decrease the shelf temperature at 1 °C/min to  
-50 °C. To ensure complete solidification, the shelf temperature was held at -50 °C for 1 h.  
Primary drying was initiated by increasing the shelf temperature at 0.5 °C/min to -25 °C. 
Chamber pressure was set to 0.066 mbar.  
Secondary drying was carried out at 20 °C for 6 h. The ramp for the shelf temperature from 
primary to secondary drying was 0.1 °C/min. After secondary drying was completed, the 
chamber was backfilled to 100 mbar with nitrogen gas and the vials were stoppered. After 
backfilling with nitrogen to atmosphere, the samples were unloaded, crimp capped and stored 
at 5 °C. 
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Table IV-2: Overview of performed freeze-drying cycles and technical setup. 
Lyo Cycle 
(LC) Formulation 
Freezing 
protocol 
Ice fog method Freeze-dryer 
Primary drying 
endpoint 
determination 
LC 1 F1, F2 CN at -3 °C 
VERISEQ® 
system 
Christ 2-12D (pressure 
control by Pirani) 
Thermocouples  
LC 2 F1, F2 CN at -10 °C 
LC 3 F1, F2 
RN equilibration 
at -3 °C 
LC 4 F1, F2 
RN equilibration 
at 2 °C 
LC 5 F1, F2 CN at -3 °C 
Millrock 
FreezeBooster® 
Millrock Magnum 
(pressure control by 
MKS) 
Thermocouples 
LC 6 F1, F2 CN at -10 °C 
LC 7 F1, F2 
RN equilibration 
at -3 °C 
LC 8 F1, F2 
RN equilibration 
at 2 °C 
LC 9 
F1, F2, F3, F4, 
F5 
CN at -3 °C 
Geidobler et al. 
Millrock Magnum 
(pressure control by 
MKS) 
Thermocouples 
LC 10 
F1, F2, F3, F4, 
F5 
CN at -10 °C 
LC 11 
F1, F2, F3, F4, 
F5 
RN equilibration 
at -3 °C 
LC 12 
F1, F2, F3, F4, 
F5 
RN equilibration 
at 2 °C 
LC 13 F1, F2 
CN at -3 °C 
performed twice 
(1 h secondary 
drying) VERISEQ® 
system 
Christ 2-12D (pressure 
control by Pirani) 
Thermocouples 
LC 14 F1, F2 
RN equilibration 
at 2 °C (1 h 
secondary 
drying) 
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IV.3.5 DATA ANALYSIS AND ILLUSTRATION 
Throughout the manuscript, error bars represent the experimental mean (based on n=10 or n=4 
(for different concentration investigation)) ± standard deviation.  
IV.3.6 OPTICAL EVALUATION OF THE FREEZE-DRIED PRODUCT 
The freeze-dried cakes were optically evaluated after drying. Parameters taken into 
consideration were compactness of the cake, contact to walls of vial, shape of the cake, color 
and overall appearance. Furthermore, photos were taken of the dried products. 
IV.3.7 KARL FISCHER TITRATION (KF) 
The residual moisture of the lyophilized cakes was determined by headspace Karl Fischer 
titration (Aqua 40.00, Analytik Jena GmbH, Jena, Germany). About 20 mg of sample was 
weighed into a 2R glass vial under a glovebox (r.h. ≤ 5%) and was analyzed at 150 °C. Prior to 
the measurements, a system suitability test was performed daily by measuring a pure water 
standard (Apura 1 water standard oven 1.0, Merck KGaA). 
IV.3.8 HEADSPACE MOISTURE MEASUREMENT BY FMS  
Headspace moisture analysis by frequency modulated spectroscopy (FMS) (LIGHTHOUSE 
FMS-1400, LIGHTHOUSE, Charlottesville, Virginia, USA) was performed to monitor water 
activity. Nitrogen was used as background gas. Prior to measurements, a calibration and a 
system suitability test with five standards was performed daily. The samples were equilibrated 
to room temperature for at least 2 h before analysis. 
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IV.3.9 NUCLEATION SUCCESS AND BATCH HOMOGENEITY 
To evaluate FMS as a non-destructive method to monitor nucleation success, a not-optimized 
nucleation protocol (TN=-3°C; injection pressure=275 mbar; VERISEQ® nucleation system) was 
used to intentionally produce ~10% not-controlled nucleated vials within the batch. Water 
activity of a full shelf (332 vials) after primary drying and incomplete (1 h) and complete (6 h) 
secondary drying was analyzed by FMS to assess batch homogeneity. 
IV.3.10 BET ANALYSIS 
The SSA of the lyophilizates was analyzed by the BET method (Autosorb-1, Quantachrome 
Instruments, Germany). Approximately 100 mg of a lyophilizate was carefully crushed with a 
spatula into small pieces and filled in a measurement tube. Prior to Krypton sorption 
measurement performed at 77.3 K, the samples were degassed for approximately 2 h at 25 °C. 
At least 5 data points were collected covering a p/p0 region of 0.05 to 0.3. In this pressure range 
the linearized version of the BET equation, used for analysis, is most reliable. The data points 
were evaluated according to the multipoint BET-method. Correlation coefficient (R2) was 
≥ 0.997 for all samples. 
IV.3.11 SCANNING ELECTRON MICROSCOPY (SEM) 
Scanning electron microscopy (SEM) was used to study the morphology of the freeze-dried 
cake. A FEI Helios G3 UC equipped with a scanning-transmission-detector (Hillsboro, Oregon, 
USA) was used to generate the images. The freeze-dried cake was broken by using a spatula. 
The generated pieces were fixed with carbon conductive cement on a sample holder in the way 
that the breakage border could be analyzed. In that way it was assured that the structure was 
not changed due to the spatula. 
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IV.4 RESULTS 
IV.4.1 PRIMARY DRYING TIMES 
Table IV-3 provides the time required to finish primary drying for all performed freeze-drying 
runs. A primary drying time reduction could only be achieved after CN at -3 °C by using 
Geidobler et al. method (LC 9) or FreezeBooster® (LC 5). All other lyo cycles led to an about 
15 h longer primary drying time of 53-60 h.  
Table IV-3: Primary drying times* of all freeze-drying cycles. It was not distinguished between sucrose and trehalose 
formulations.  
Nucleation method/  
freeze-dryer 
CN-3 °C CN-10 °C RN equi -3 °C RN equi 2 °C 
VERISEQ® system/ 
Christ 2-12D  
(Pirani gauge) 
56 h 60 h 56 h 57 h 
Millrock FreezeBooster®/ 
Millrock Magnum 
(MKS) 
43 h 55 h 55 h 59 h 
Geidobler et al./ 
Millrock Magnum 
(MKS) 
41 h 53 h --- 57 h 
* the time when the shelf temperature reached -25 °C until the thermocouples indicated the end of primary drying 
was considered as primary drying time. 
IV.4.2 NUCLEATION SUCCESS AND BATCH HOMOGENEITY 
For monitoring the success of CN, a non-destructive method was necessary to identify samples 
that have undergone CN and to make them available for further analysis. Within this study, we 
used the visible difference in cake appearance between controlled nucleated and not-controlled 
COMPARISON OF ICE FOG METHODS AND MONITORING OF CONTROLLED NUCLEATION SUCCESS 
AFTER FREEZE-DRYING 
85 
nucleated lyophilizates, and the difference in water activity, determined by FMS, to assess the 
successful performance of CN.  
RN lyophilizates showed a compact cake with minor shrinkage in height and isolated shrinkage 
in diameter, a shiny surface and tiny cracks. CN lyophilizates differed and had a more porous, 
loose and shiny structure. Additionally, crack formation was more pronounced in CN cakes 
(Figure IV-2).  
     
Figure IV-2: (A) Vial photos from LC 3 (Sucrose). Controlled nucleated vial (left): more porous and loose structure. 
Random-nucleated vial (right): less porous, more compact structure. (B) CN: Example of a vial of LC 7 (Sucrose). (C) RN: 
Example from LC 8 (Sucrose). 
With FMS the partial pressure of water vapor (pH2O), which corresponds to the water activity in 
the vial headspace, was determined in a fast and non-destructive way. CN samples had higher 
water activity (pH20=0.6-0.8 mbar for LC 1 and 2) compared to RN vials (pH2O=0.1-0.2 mbar for 
LC 3 and pH2O=0.2-0.4 mbar for LC 4) (Figure IV-3). Based on this difference, it was possible to 
identify not-controlled nucleated vials also within a batch and thus monitor CN success by FMS 
measurements (Figure IV-3, LC 1; not-controlled nucleated vials are indicated in light grey). The 
not-optimized CN protocol of LC 1 (TN=-3 °C; induction pressure=275 mbar; VERISEQ® 
nucleation system) resulted in 43 not-controlled nucleated vials (indicated in light grey) out of 
332 vials of the shelf (=13%). In contrast, for the CN protocol in LC 2 at a lower TN, only 1 vial 
out of 332 vials (< 1%) did not undergo controlled nucleation.  
A B C 
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Figure IV-3: FMS data of complete freeze-dryer shelves à 332 vials of LC 1, LC 2, LC 3 and LC 4 (Sucrose-based formulation 
F1); not-controlled nucleated, defective vials within a CN lyophilization cycle are indicated in red.  
We additionally investigated the FMS data shown in Figure IV-3 with respect to batch 
homogeneity only considering the vials that underwent controlled nucleation. A detailed 
evaluation of the relative and absolute standard deviations (rel STD and abs STD, respectively), 
provided in Table IV-4, illustrated that the determined rel STD for the CN-10 °C (LC 2), RN 
equi -3 °C (LC 3) and RN equi 2 °C (LC 4) runs were comparable with 9.0, 9.5, and 9.6%, 
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respectively. Although, the defect vials had been excluded, the shelf processed by LC 1 showed 
a slightly higher rel STD of 10.5% compared to the other cycles after 6 h of secondary drying.  
Table IV-4: Determined absolute and relative standard deviations for all shelves and both secondary drying times. 
Nucleation  
protocol 
Secondary 
drying 
duration 
Mean: Partial 
pressure of water 
vapor [mbar] 
Absolute  
STD [mbar] 
Relative 
 STD 5 [%] 
Residual 
moisture [%] 
of 10 vials 
CN -3 °C* 
6 h 
0.80 0.08 10.5 0.92 
CN -10 °C 0.80 0.07 9.0 1.51 
RN equi -3 °C 0.23 0.02 9.5 1.00 
RN equi 2 °C 0.40 0.04 9.6 0.97 
CN-3 °C 
1 h 
4.84 0.4 7.6  
RN equi 2 °C 1.38 0.2 13.1  
*not-optimized protocol: defective, not-controlled nucleated vials (~13%) have been excluded from analysis. 
To study how batch homogeneity after CN develops during the process, we performed LC 13 
and LC 14 (Figure IV-4). Both cycles were terminated after 1 h of secondary drying. In fact, after 
incomplete secondary drying, vials from a CN process showed a lower rel STD (7,3%) than RN 
vials (13.1%), but after 6 h the difference vanished, and CN and RN revealed about the same 
rel STD (Table IV-4). Thus, CN did not improve homogeneity with respect to RM.  
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Figure IV-4: FMS analysis of complete freeze-dryer shelves à 332 vials of LC 13 and LC 14 (Sucrose-based formulation 
F1); not-controlled nucleated vials within a CN lyophilization cycle are indicated in red. 
IV.4.3 ANALYSIS OF PRODUCT PROPERTIES 
Three ice fog methods and the resulting product properties of the lyophilizates, such as optical 
appearance, microscopic structure and morphology, SSA, and RM were compared. 
Additionally, the impact of TN and formulation composition on these product properties was 
assessed. All vials used for the analysis of product properties were tested visually and by FMS 
for successfully performed controlled nucleation. 
As for LC 1, a non-optimized protocol was used to evaluate FMS as a monitoring tool for 
nucleation success, lyophilizates generated by LC 1 were not included in this section. 
IV.4.3.1 CAKE APPEARANCE 
As described above, CN lyophilizates differed in cake appearance from RN samples 
independent of the nucleation method and formulation. However, for sucrose-based 
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lyophilizates an impact of TN was observed (Figure VIII-15): CN -3°C lyophilizates showed a 
porous and loose structure with minor shrinkage in height and substantial crack formation. 
CN-10 °C lyophilizates were more compact, less porous with reduced crack formation. 
Sucrose-based RN samples equilibrated at -3 °C or at 2 °C had a compact cake, with minor 
shrinkage in height, only isolated tiny crack formation and negligible shrinkage in diameter. No 
difference between the nucleation methods was detected. 
For trehalose-based samples (Figure VIII-16), most of the samples revealed the same 
dependency on TN as noted for the sucrose-based products. Exclusively the CN-10 °C 
Geidobler et al. vials (LC 10) did not differ from the CN-3 °C samples. Again, all RN samples 
appeared comparable with a compact cake and minor shrinkage in height. However, the RN 
equi-3 °C 2-12D products (LC 3) showed adhesion to the vial wall in contrast to all other RN 
samples.  
IV.4.3.2 SEM  
After macroscopic characterization, microscopic analysis of the lyophilizates was performed by 
SEM. All lyophilizates had a sponge like morphology in common. 
Sucrose-based samples (Figure IV-5): The CN lyophilizates showed, as expected, larger pores 
than RN products. Again, a dependency of TN was observed, as CN-3 °C resulted in larger 
pores compared to CN-10 °C. The smallest pores were noted for the RN protocols. All 
nucleation methods resulted in similar pore size and morphology. Additionally, no difference in 
RN lyophilizates was detected between the freeze-dryers. 
Trehalose-based samples (Figure IV-6): Like for the sucrose-based formulation, a smaller pore 
size was observed for CN-10 °C as compared to CN-3 °C in all cases. All nucleation methods 
resulted in comparable microscopic appearance. RN equilibrated at 2 °C samples processed in 
the 2-12D freeze-dryer (LC 4) showed slightly larger pores than the other RN lyophilizates.    
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Figure IV-5: SEM images of all freeze-drying cycles of the sucrose-based samples. 
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Figure IV-6: SEM images of all freeze-drying cycles of the trehalose-based samples. 
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IV.4.3.3 BET  
The lyophilizates were analyzed by Krypton gas adsorption to determine the SSA (Figure IV-7). 
In accordance with the SEM images, CN lyophilizates of both formulations showed, reciprocally 
to pore size, lower SSA compared to the RN protocols. Sucrose-based lyophilizates generated 
by FreezeBooster® (LC 5 and 6) and according to Geidobler et al. (LC 9 and 10), showed an 
increase in SSA with decreasing TN (Figure IV-7A). These two methods showed similarly low 
SSA values at a TN of -3 °C and -10 °C, whereas for VERISEQ® CN-10 °C lyophilizates slightly 
higher SSA values were determined. RN samples generated in a Christ 2-12D and a Millrock 
Magnum freeze-dryer resulted in similar SSA values.  
For trehalose-based products generated by FreezeBooster® (LC 5 and 6) and Geidobler et al. 
(LC 9 and 10), SSA was independent from TN, as CN-3 °C and CN-10 °C resulted in comparable 
SSA (Figure IV-7B). All CN methods resulted in assimilable SSA values. SSA values of RN equi 
2 °C lyophilizates were comparable between freeze-dryers. For trehalose-based samples, 
higher SSA values as for the corresponding sucrose-based samples were detected.  
  
Figure IV-7: Results of BET measurements of all runs. (A) sucrose formulation. (B) Trehalose formulation.  
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To investigate the impact of formulation composition on SSA, besides CN and TN, mAb 
concentration was varied. Formulations (sucrose-based) in the concentration range from 
1-100 mg/ml mAb were subjected to three different nucleation protocols.  
Independent of the mAb concentration, an increase of SSA was found with decreasing TN 
(Figure IV-8). Furthermore, the characteristically lower SSA for CN sampes was determined 
throughout all mAb concentrations.  
 
Figure IV-8: BET results of all mAb concentrations and TN processed according to the Geidobler et al. method in the 
Millrock Magnum Freeze-Dryer. 
IV.4.3.4 KF RESULTS 
RM of the freeze-dried products was assessed by KF titration. In accordance with the SEM 
images and BET results, CN lyophilizates showed the expected higher RM compared to the RN 
samples.  
Sucrose-based lyophilizates (Figure IV-9A): No dependency of RM on TN was detected (similar 
RM values for CN-3 °C and CN-10 °C). Slightly higher RM values were determined for 
Geidobler et al. samples (LC 9 and 10) compared to FreezeBooster® lyophilizates (LC 5 and 6). 
At CN-10 °C, VERISEQ® lyophilizates (LC 2) exhibited higher RM values (1.5%) as the other 
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two methods (FreezeBooster®=1.2% (LC 6), Geidobler et al.=1.3% (LC 10). The two RN 
protocols resulted in assimilable RM values.  
Trehalose-based products (Figure IV-9B): Like the sucrose-based samples, lyophilizates 
generated by VERISEQ® nucleation system had the highest RM values compared to the other 
two methods. The lowest RM values were detected for Millrock FreezeBooster® processed 
samples. Additionally, FreezeBooster® and Geidobler et al. processed samples revealed a 
decrease in RM content with decreasing TN. No trend between the RN samples equilibrated 
at -3 °C and 2 °C could be noted.  
  
Figure IV-9: Results of Karl Fischer measurements of all runs. (A) sucrose formulation. (B) trehalose formulation. 
Similar to BET sample set, formulations with different mAb concentrations (sucrose-based) 
were analyzed to assess the impact of formulation composition on RM. As expected and in 
accordance with SSA results, higher RM content was detected for CN lyophilizates compared 
to RN products independent of the protein concentration (Figure IV-10). A decrease in RM with 
a decrease of TN was found independent of mAb concentration.  
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Figure IV-10: KF results of all mAb concentrations and TN processed according to the Geidobler et al. method in the 
Millrock Magnum Freeze-Dryer.  
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IV.5 DISCUSSION 
IV.5.1 MONITORING OF NUCLEATION SUCCESS AND BATCH 
HOMOGENEITY  
As CN is known to change product properties [7, 9, 21, 28], a non-destructive, high-throughput 
method to monitor CN success as 100% control is required. In this study, we applied FMS as 
such a method (5 seconds per vial) to monitor nucleation success via analysis of water activity 
as surrogate for residual moisture. By using FMS, it was possible to distinguish between CN 
vials, showing high residual water activity, and RN samples, showing low residual water activity 
within one batch (Figure IV-3, LC 1). All samples detected as not-controlled nucleated by FMS 
within a batch could be identified and were excluded from further analysis by SEM, BET and 
KF, when we compared the effects of the nucleation process on the product properties. The 
ability to detect these defects within a batch could be used for optimization and validation of the 
CN process and even in commercial production for quality assurance.  
Obviously, the target would be 100% successfully controlled nucleated vials within one batch. 
For the proof-of-concept, we applied a not-optimized CN protocol using the VERISEQ® 
nucleation system. This system generates a very fine ice fog dispersion from liquid nitrogen and 
water vapor, in contrast to the snow-flake like ice fog structures that we observed during 
condenser loading of the FreezeBooster®. Additionally, the CN by the VERISEQ® method was 
performed at a comparably high chamber pressure (VERISEQ®: 275 mbar; FreezeBooster®: 
66 mbar; Geidobler et al: 3.7 mbar), thus, the resistance for the very fine ice fog within the 
chamber was approximately 4 or 74 times higher in the VERISEQ® method compared to 
FreezeBooster® or Geidobler et al., respectively. This resulted in a defect rate of 13% (Figure 
IV-3, LC 1). By lowering the nucleation temperature, the probability for controlled nucleation 
strongly increases. By this, we were able to reduce the number of defects from 43 (13%) to 1 
vial (0.3%) (Figure IV-3, LC 2).  
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The generated FMS data was further analyzed to assess batch homogeneity. CN is expected 
to facilitate scale-up and process transfer by overcoming the stochastic nature of ice nucleation 
and a consequently more homogeneous drying behavior [10-12]. Mainly two different 
approaches to determine homogeneity have been used: (i) analysis of individual vials and (ii) 
batch-representative methods. Rambhatla et al. [9] for example, used the standard deviation of 
BET measurements of the final product (n=3) as surrogate for nucleation homogeneity. In a 
different approach, Fang et al. [23] chose the standard deviation of measured LDH activity and 
tetramer recovery (n=6) to assess homogeneity. Given the small number of replicates, it may 
be difficult to extrapolate the results to a full batch. In contrast, Passot et al. [12] evaluated the 
degree of homogeneous drying by comparing the absolute value of the slope of the Pirani gauge 
profile. With this method, they were able to consider the average drying behavior for a complete 
batch (n=100). However, the homogeneity of the residual water content at the end of primary 
drying was considered instead of the final product homogeneity. Similarly, Oddone et al. [11] 
studied the homogeneity of drying behavior of a whole batch (n=70) by determining the 
onset-offset time of the pressure ratio curve as a surrogate for vial batch behavior.  
By comparing CN and RN processed shelves after complete and incomplete drying, we 
investigated if the homogeneity generated through the freezing step is maintained through the 
lyophilization cycle until the final product. We excluded the not-controlled nucleated vials from 
analysis. When determining the homogeneity after 1 h of secondary drying, we found a 
remarkably improved homogeneity for CN samples compared to RN samples (rel STD of 7.6% 
for CN-3 °C vs 13.1% for RN equi 2 °C). These results confirmed the findings of Passot et al. 
and Oddone et al. and indicate that CN could be beneficial to transfer primary drying protocols 
from development to production scale freeze-dryers [11, 12]. However, after completing the 
cycle, after 6 h of secondary drying, inter-vial batch homogeneity between CN and RN protocols 
was practically identical, which confirms the results of Arsiccio et al.[29]. Based on that data, 
we suggest that the initially higher heterogeneity after RN did not result in a reduced inter-batch 
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homogeneity of the final product. Presumably, desorption during secondary drying overrules 
small differences in RM content of individual vials. 
IV.5.2 COMPARABILITY OF NUCLEATION METHODS WITH RESPECT TO 
PRODUCT PROPERTIES 
As mentioned above, CN is expected to facilitate scale-up because TN can be kept from lab to 
production scale [7, 9, 10]. Different technologies are available to control TN and to induce ice 
nucleation. However, not every method can easily be implemented in lab and production scale 
equipment [18]. Thus, it is of high interest to investigate the comparability of CN methods with 
respect to product properties. If different CN methods result in comparable product properties, 
the most convenient and suitable CN method for the freeze-dryer could be chosen and thus 
expensive retrofits and investments could be avoided. Therefore, we investigated the 
comparability of three ice fog methods, the VERISEQ® nucleation system, the FreezeBooster® 
and the method described be Geidobler et al [25], which differ in ice fog generation temperature 
and induction pressure. The three ice fog methods were compared with respect to primary 
drying time and product properties such as SSA and RM for two different sugar-based 
formulations. These product parameters correlate as TN defines the pore size; a high TN =-3 °C 
results in larger pores and by this reduced product resistance and faster primary drying. The 
larger pores can be detected by SEM and a reciprocally low SSA can be measured, which in 
turn hinders desorption during secondary drying and leads to a higher RM content [7, 9].  
Comparable to the results of Gitter et al. [20], all applied nucleation methods resulted in similar 
cake appearance for the different nucleation protocols (TN) and both sugar formulations. Minor 
differences in terms of contact with the vial wall were not considered as critical, because all 
methods and protocols resulted in an elegant cake. SEM micrographs confirmed the results of 
primary drying time evaluation. The larger pores generated by FreezeBooster® and Geidobler 
et al. method at CN-3 °C led to reduced product resistance and consequently reduced primary 
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drying times. All nucleation methods showed PD times at CN-10 °C, close to or even 
comparable to the RN cycles. It can be assumed that the smaller pore size generated at 
CN-10 °C (Figure 5 and 6) resulted in higher product resistance and thus longer primary drying 
times, compared to CN-3 °C samples. The three methods resulted in comparable product 
properties, such as pore size and structure (Figure IV-5 and Figure IV-6) as well as SSA values 
with only minor differences in RM content between the methods (Figure IV-10).  
IV.5.3 SSA DETERMINING FACTORS: CN, TN AND FORMULATION 
COMPOSITION 
Already in 1925, Tammann reported that the ice crystal morphology is a unique function of TN 
[30]. Luyet and Rapatz [31] found a variety of ice crystal morphologies, including hexagonal, 
dendritic and dispersed spherulitic morphologies. The morphologies were dependent on TN, 
solute and concentration. In the more recent studies [4, 7, 9], TN was also identified to be the 
determining factor for the ice morphology and consequently, the ice crystal size and thus the 
SSA of the freeze-dried product. Another factor, which can impact the SSA and should be 
accounted for is the roughness of the pore surface. The roughness can vary for a given 
formulation, if the formulation contains e.g. crystallizing excipients [32]. We observed in a 
previous study, that CN-3 °C and CN-10 °C CN samples resulted in comparable SSA and 
therefore suggested that TN is not the only SSA determining factor when an ice fog method is 
used [24]. Bhatnagar et al. [33] investigated the effect of a change in formulation composition 
at a controlled ice nucleation temperature on the SSA. To further investigate this observation, 
we applied two different ice fog methods, which differed in ice fog generation and injection 
pressure at two different TN. CN-3 °C and CN-10 °C were chosen as desired TN to test the 
presumed limits of feasible controlled nucleation temperatures with -3 °C being the highest 
applicable TN with satisfying nucleation success and -10 C being the lowest applicable TN 
without risking spontaneous random nucleation. By including two sugar formulations, sucrose 
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and trehalose-based, and four mAb concentrations, we examined the formulation effect on the 
resulting SSA.  
For the sucrose-based formulation, we determined a correlation between SSA and TN for the 
FreezeBooster® and Geidobler et al method (Figure 7A and B). Trehalose-based lyophilizates 
did not show a difference between the CN-3 °C and the CN-10 °C samples, which confirmed 
our suggestion that if CN is applied TN is not the only SSA determining factor. Additionally, the 
fact that CN-10 C samples revealed lower SSA compared to RN samples, although TN was in 
the same range, supported the theory that the application of an ice fog CN method itself impacts 
the ice crystal structure and thus primary drying behavior. Furthermore, the resulting SSA was 
shown to be dependent on the formulation as sucrose-based and trehalose-based samples did 
not exhibit the same SSA, which confirmed the results of Luyet and Rapatz [31] and Bhatnagar 
et al. [33]. However, the mAb concentration did not notably impact the resulting SSA (Figure 8). 
Throughout the mAb concentrations tested (1-100 mg/ml), the observed correlation between TN 
and resulting SSA for sucrose-based lyophilizates was detected. Thus, pore size and SSA were 
dependent on the application of an ice fog CN, the formulation and not only TN. Thus, for CN 
process development it should be considered that a high TN (e.g. -3 °C) does not necessarily 
result in a relevant reduction of primary drying time; especially when considering the prolonged 
equilibration time but poses a higher risk for not-controlled nucleated vials within a batch. On 
the other hand, a low TN (e.g. -10 °C) constitutes a risk of spontaneous nucleation of isolated 
vials. Therefore, it is recommended to choose a robust TN (e.g. -5°C to -8°C) focusing on 100% 
successful CN of the batch.   
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IV.6 CONCLUSION 
Recently, great expectations were raised on CN, such as primary drying time reduction, 
improved batch homogeneity or facilitated scale-up and process transfer. However, the 
achievement of these goals by CN practically faces some challenges.  
Within this study, we could show that FMS is a promising tool that enables non-destructive high 
throughput measurements of nucleation success and with this could support the validation of a 
CN process.  
We detected an improved inter-vial batch homogeneity after primary drying for CN samples 
compared to RN samples. Although this suggests that CN could facilitate scale-up of 
freeze-drying processes, we observed that after complete secondary drying initial advantages 
in homogeneity for CN processes are no longer present.  
Furthermore, we exhibited that three ice fog methods, VERISEQ® system, FreezeBooster® and 
Geidobler et al., resulted in similar product quality attributes with only slight differences in RM 
of the product cakes. Thus, we assume that different ice fog CN methods can be applied in 
development and production scale with a low risk of changing the product properties.  
Finally, we conclude that TN is not the only determining factor for ice morphology and 
consequently SSA. Aside from TN, the fact whether nucleation was induced by an ice fog method 
or occurred randomly and the used formulation (sugar) impacted the SSA. Consequently, a 
higher TN does not necessarily lead to additional primary drying time reduction compared to a 
TN that safely assures 100% controlled nucleation of the product vials.  
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V.1 ABSTRACT 
This study investigates the suitability of heat flux measurement as a new technique for 
monitoring product temperature and critical endpoints during freeze-drying. The heat flux sensor 
is tightly mounted on the shelf and measures non-invasively (no contact with the product) the 
heat transferred from shelf to vial. Heat flux data were compared to comparative pressure 
measurement, thermocouple readings and Karl Fischer titration as current state of the art 
monitoring techniques. The whole freeze-drying process including freezing (both by ramp 
freezing and controlled nucleation), primary and secondary drying was considered. We found 
that direct measurement of the transferred heat enables more insights into thermodynamics of 
the freezing process. Furthermore, a vial heat transfer coefficient can be calculated from heat 
flux data, which ultimately provides a non-invasive method to monitor product temperature 
throughout primary drying. The endpoint of primary drying determined by heat flux 
measurements was in accordance with the one defined by thermocouples. During secondary 
drying, heat flux measurements could not indicate the progress of drying as monitoring the 
residual moisture content. In conclusion, heat flux measurements are a promising new 
non-invasive tool for lyophilization process monitoring and development using energy transfer 
as a control parameter. 
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V.2 INTRODUCTION 
Freeze-drying is the method of choice to dry temperature sensitive products such as 
pharmaceutical proteins, peptides, and vaccines. However, freeze-drying cycles need product 
specific optimization to ensure, for example, that the product temperature (Tp) does not exceed 
the critical product temperature during primary drying and that primary drying is completed. 
Non-optimized processes can result in elevated residual moisture, cake shrinkage or even cake 
collapse, and can ultimately lead to the rejection of an entire production batch [1, 2]. Thus, the 
accurate monitoring of Tp and the determination of the end of primary and secondary drying are 
crucial to assure product quality and process economy [2]. Consequently, the need for rigorous 
product monitoring and process analytical technology (PAT) tools during cycle development is 
high. 
Temperature sensors, such as thermocouples (TC), wireless temperature sensors, or 
resistance temperature detectors (RTD) [3, 4], are commonly used to monitor the product 
temperature and to assess the completion of primary drying (i.e. when Tp approaches the shelf 
temperature). However, inserting a temperature sensor into a vial can increase sublimation 
rates compared to unmonitored vials. Hence, monitored vials complete primary drying earlier 
and may not be batch representative [5]. Tang and Pikal recommended the inclusion of a safety 
margin or a “soak time” for the use of thermocouples to ensure that all vials have finished 
primary drying [6]. More recent studies performed by Bosca et al. [7] have shown that in non 
GMP conditions the cake structure and product temperature in monitored and unmonitored vials 
are comparable. Additionally, product dynamics are almost unaffected by the insertion of a 
thermocouple [7]. However, temperature sensors are usually handled manually, which poses a 
challenge with respect to sterility [5]. 
Other methods to determine the product temperature and the end of primary drying are based 
on pressure rise tests (PRT) and mathematical modeling. In early works, product temperature 
and completion of primary drying was estimated based on the saturating vapor pressure of ice 
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by the pressure response measured during a PRT [8, 9]. Another method to use PRT data for 
product temperature estimation is barometric temperature measurement (BRT), where the 
maximum value of the first derivative of the pressure rise curve is used to estimate the 
temperature at the sublimation interface [10, 11]. Further, several mathematical models based 
on PRT data, such as manometric temperature measurement (MTM) [12-15], pressure rise 
analysis (PRA) [16] and dynamic parameters estimation (DPE) [17] were proposed in literature 
to determine product temperature and assess various process parameters. These methods 
allow for a non-invasive estimation of the product temperature at the sublimation interface, 
reducing the impact on product sterility [1, 18]. They all provide an average product temperature, 
which does not account for heterogeneities across the batch (edge vials (higher temperatures) 
and centre vials (lower temperatures)) [19]. For MTM, for example, it has been described that 
the estimated product temperature is more representative for the lowest product temperature 
[13]. The named mathematical models differ by the used algorithm and the parameters 
estimated [18]. 
Comparative pressure measurement is yet another way of assessing the end of primary drying, 
where a Pirani pressure gauge and a capacitance manometer are employed. During primary 
drying, the measured pressure differs between the two instruments, while at the end of primary 
drying this difference approaches zero. The comparative pressure measurement is also a batch 
representative and non-invasive method that accounts for the very last vials to complete primary 
drying [1, 2, 4].  
Additionally, electronic moisture sensors have been described as a technique for assessing the 
end of primary drying by Roy and Pikal [5]. The electronic moisture sensor detects a change in 
capacitance based on the adsorption of water on a thin aluminum oxide film. The capacitance 
measurement is translated into a voltage output. Roy and Pikal showed that the sensor is able 
to detect as few as approximately 0.3% of not completely dried vials and is therefore a batch 
representative method. However, it needs to be noted that the sensor is not able to withstand 
steam sterilization [5].  
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In the last years, substantial effort has been made to implement new technologies to monitor 
the end of primary drying and to facilitate process development and transfer. Examples are 
mass spectrometry (MS) [20, 21], optical fiber system (OFS) [22], and tunable diode laser 
absorption spectroscopy (TDLAS) [23, 24].  
Mass spectrometry is used for residual gas analysis. Therefore, a mass spectrometer is 
connected directly to the freeze-dryer chamber or as an alternative to the duct between the 
chamber and the condenser. The gas composition during primary drying changes with ongoing 
drying time. At the beginning of the primary drying step water vapor is the most predominant 
gas species. When all ice is sublimed, the amount of water vapor steeply decreases, and 
nitrogen becomes the more dominant gas species. Residual gas analysis by mass spectrometry 
not only allows for assessing the end of primary drying but also for the detection of leaks of the 
drying equipment as up to 16 components can be monitored simultaneously [20, 21]. However, 
this technique lacks the ability to monitor product temperature.  
Kasper et al. introduced an OFS based on Fiber Bragg Gratings to monitor product temperature 
and the end of primary drying. The OFS was shown to be significantly more sensitive and easier 
to handle compared to thermocouples. Further, they showed a better resolution and a faster 
response which even allows for the detection of physico-chemical events such as crystallization. 
Kasper et al. could also show that modifications of the OFS even enable a non-invasive 
temperature monitoring and end point determination [22].  
TDLAS is another non-invasive method to monitor a freeze-drying cycle. This sensor simply 
requires optical access to the gas flow in the duct between the chamber and the condenser and 
can be implemented in freeze-dryers of various scales, which facilitates scale up. Gieseler et 
al. [23] have shown that the TDLAS technique is able to determine the water vapor 
concentration, gas flow velocity and the rate of water removal. The knowledge of the water 
vapor concentration enables the detection of the endpoint of primary and secondary drying [23]. 
Further work by Schneid et al. [24] describes the application of TDLAS to determine an average 
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sublimation rate, which can provide the vial heat transfer coefficient (Kv) and an average product 
temperature. Kuu et al. [25] further demonstrated the assessment of the product mass transfer 
resistance by TDLAS measurements and a pore diffusion model. However, it needs to be noted 
that it is not possible to retrofit the system into each freeze-dryer [23, 26].  
Currently, only few methods allow detecting the end of secondary drying. These include 
methods based on pressure rise testing [3], MTM method [14], and electronic moisture sensors 
[5, 27]. Techniques such as sample thieves or single shelf closure systems enable the extraction 
of products directly from the freeze-drying process for the determination of the residual moisture 
at different time points [3]. 
A new and interesting approach to monitor Tp and critical end points is measuring the heat flux 
between shelf and vial(s). Heat flux sensors have been used in plastics-, automotive-, or solar 
energy industry [28], whereas the application as a monitoring and PAT tool in pharmaceutical 
freeze-drying has not been established yet. For heat flux measurement during freeze-drying, a 
heat flux sensor is used, which utilizes a thin foil type thermopile. A thermopile is an array of 
approximately 50-60 differential thermocouples connected in series that convert thermal energy 
into electrical energy. In a heat flux sensor, the thin foil type thermopile is bound to both sides 
of a known thermal barrier. The voltage output of each thermocouple of the thermopile is 
proportional to the temperature difference (ΔT) between the upper and the lower surface. In 
turn, ΔT is directly proportional to the heat flux through the sensor. Thus, the sensor needs to 
be placed in direct contact with the surface of interest, in our case the freeze-dryer shelf and 
the vial bottom. Generally, these sensors are able to measure heat flux resulting from 
conductive, convective, and radiation heat transfer [28]. As the sensor is placed between the 
vials and the shelf, it consequently measures mainly conduction and convection heat at that 
point.  
The heat flux sensors evaluated within our study detect the ΔT between the shelf surface 
temperature (Ts) and the vial bottom temperature considered as product temperature (Tp). The 
measured temperature difference is transferred via the thickness of the sensor (0.18 mm) and 
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its thermal conductivity to an average amount of thermal energy that has been transferred per 
unit time per unit area. The area calculation is based on the area of the sensor. Thus, the heat 
flux sensor gives a direct reading in W/m2. Throughout a freeze-drying cycle, the heat flux 
direction changes. During freezing, the heat flows from the warmer vial to the colder shelf 
surface, which results in a negative heat flux. During primary and secondary drying, heat flux is 
positive as long as heat flows from the shelf to the vials. This could also be used to determine 
the end of ice crystallization during freezing, because the generated exothermic heat warms the 
vial during ice formation, whereas the vial temperature approaches the Ts after the crystallization 
event [29]. Furthermore, during primary drying, when the vials reach Ts, heat flux approaches 
zero indicating the end of primary drying. 
Moreover, heat flux measurements can provide important parameters for process development 
and control such as the vial heat transfer coefficient (Kv). Kv is influenced by different factors, 
such as vial type, geometry of the vial bottom and chamber pressure. Therefore, Kv needs to 
be determined for every setup of chamber pressure, shelf temperature and vial type [30]. 
Currently, gravimetrical approaches requiring time consuming weighing of numerous vials is 
typically used for Kv determination. Heat flux measurements could provide a fast, simple and 
non-invasive alternative. However, it should be noted that the vial heat transfer coefficient 
determined by heat flux measurement (Kv(heat flux)) differs from the Kv determined by 
gravimetrically measurements (Kv(gravimetrically)) and calculated as described by Pikal et al. 
[30], because the Kv(heat flux) comprises not for all heat transfer mechanisms in contrast to the 
Kv(gravimetrically). This can be explained by the sensors positioning below the vial. Heat 
supplied to the product by radiation effects is consequently not detected in completion. 
Therefore, the Kv(heat flux) is lower as the Kv(gravimetrically). This has been shown in previous 
work [31]. Additionally, mass flow per vial, mass flow of the entire batch, fraction of removed 
mass and the product resistance (Rp) could be assessed by heat flux measurements. Ultimately, 
from Rp, Tp at the sublimation interface could be calculated. 
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Besides process monitoring, the heat flux can also be used to control freeze-drying processes. 
For process control, the shelf temperature set point could be adjusted based on the measured 
heat flux in order to achieve maximum heat transfer while Tp is kept below the critical product 
temperature. 
Our aim was to evaluate the performance and suitability of heat flux measurements for 
freeze-drying process monitoring under pharmaceutically relevant conditions. The heat flux data 
measured with the applied AccufluxTM sensors were compared to current state of the art 
techniques to monitor freeze-drying processes, such as comparative pressure measurement 
and TC readings for the end of primary drying. During secondary drying, the results from heat 
flux measurements were compared to product moisture determined by Karl Fischer titration and 
head space moisture analysis. Further, the accuracy of Kv(heat flux) for product temperature 
estimation was investigated by comparing the estimated product temperature with actual 
thermocouple readings. 
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V.3 MATERIALS AND METHODS 
V.3.1 FORMULATIONS AND PRIMARY PACKAGING  
Ph.Eur grade sucrose and bovine serum albumin (BSA) was purchased from Sigma-Aldrich 
(Munich, Germany). Sucrose solutions (5%, 20%, and 50% weight/volume (w/v) ratios) were 
prepared with highly purified water (Milli-Q integral water purification system, Merck Millipore, 
Hertfordshire, United Kingdom). BSA (10 mg/ml) was dissolved in a 10 mM phosphate buffer at 
pH 7.4 containing 5% sucrose as cryoprotectant. Prior to use, all formulations except the 50% 
sucrose solution were filtered through 0.22 µm PVDF membrane filters (Millipore, Schwalbach, 
Germany).  
2R glass type I tubing vials and 10R tubing vials were kindly provided by MGlas AG 
(Münnerstadt, Germany). Rubber stoppers, 13 mm and 20 mm (Westar® RS, FluoroTec B2-40 
coating) were kindly supplied by West Pharmaceutical Services (Eschweiler, Germany). For 
investigations on the 1st generation sensor 2R tubing vials with a filling volume of 1 ml were 
used. For evaluation of the 2nd generation sensor, 10R tubing vials were filled with 1, 3, 5 ml 
formulation depending on the experiment (details stated in each section).  
V.3.2 FREEZE-DRYING EQUIPMENT AND PROCESS DESIGN 
A pilot scale freeze-dryer (Millrock Magnum Series; 1.48 m2) equipped with a Millrock 
FreezeBooster® for automatic controlled nucleation was used for the experiments. Three heat 
flux sensors (AccufluxTM, Millrock Technology Inc., Kingston, NY, USA) are mounted on the 
middle shelf of the freeze-dryer (Figure 1B) and the corresponding control software (LyoPAT®, 
Millrock Technology Inc., Kingston, NY, USA) is installed. 
Freeze-drying process parameters and freezing protocols by random (RN) or controlled 
nucleation (CN) are summarized in Table V-1. After freezing, the samples produced by both 
nucleation protocols were subjected to the same primary and secondary drying protocol. For 
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some experiments within this study, the standard drying protocol was varied, which is stated in 
the result section where applicable.  
Table V-1: Freeze-drying protocol used for the experiments. 
Process step Controlled nucleation (CN) Random nucleation (RN) 
Equilibration Equilibration at desired TN (-5 °C) for 
120 min 
Equilibration at 2 °C for 120 min 
Nucleation Controlled at -5 °C Random by shelf temperature decrease by 
1 °C/min 
Freezing Decrease of shelf temperature to -50 °C (ramp 1 °C/min); hold for 120 min 
Primary drying Shelf temperature: -25 °C (ramp 0.5 °C/min) 
Chamber pressure: 100 mTorr 
Secondary drying Shelf temperature: 30 °C (ramp 0.1 °C/min) 
Chamber pressure: 100 mTorr 
 
The end of primary drying was determined by comparative pressure measurement, unless 
stated differently in the result section.  
V.3.3 HEAT FLUX SENSORS  
AccufluxTM heat flux sensors (Millrock Technology Inc., Kingston, NY, USA) of two different 
generations were used within this work. The 1st generation sensor measures 4 x 1.4 cm and 
has an external thermocouple mounted next to the sensor on the shelf to measure the shelf 
temperature (T-type Copper). The 2nd generation sensor measures 3.6 x 3 cm and is equipped 
with a built-in thermocouple to measure the shelf temperature (ANSI Type T). To improve a flat 
standing of the vials, approximately 2 cm of stainless-steel tape of the same thickness as the 
sensor (called “Scaffolding”) are mounted around the 2nd generation sensors (Figure V-1A). 
Both sensors are permanently fixed on the shelf with a conductive, silver filled epoxy (AI Technology 
Inc., Princeton, NJ, USA). The surface of the sensor, where the vials are placed on, is made of 
stainless-steel tape (total thickness of sensor and stainless-steel tape: 0.28 mm). The thermal 
resistance of the sensor (sensor thickness measures 0.18 mm) is 0.0013 K/m2/W and the heat 
capacity value is 29.8 cal/m2/K. The sensor´s response time corresponds to 0.60 seconds.  
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Figure V-1: (A) Schematic drawing of the heat flux sensor mounting; the 1st generation sensor lacks the scaffolding. In 
consequence, vials, which overhang, cannot be placed evenly. Scaffolding was added to the 2nd generation sensor, which 
ensures a better leveled vial position. (B) Schematic drawing of the freeze-dryer shelf, which the sensors are mounted on 
(drawing to scale). 
The 1st generation sensor was mounted in the center of the shelf. One 2nd generation sensor 
was added right next to the 1st generation sensor in the center of the shelf. The other 2nd 
generation sensor was placed in the front left corner of the shelf. An overview about the positions 
of the different sensors on the shelf is provided by (Figure V-1B). All sensors were calibrated by 
the manufacturer (RdF corporation, Hudson, NH, USA). The measurement output data of the 
sensors was processed via the corresponding LyoPAT® software (Millrock Technology Inc., 
Kingston, NY, USA), which was part of the freeze-dryer controlling software.  
V.3.4 DETERMINATION OF THE VIAL HEAT TRANSFER COEFFICIENT BY 
HEAT FLUX (KV, (HEAT FLUX))  
The heat flux sensor can be used to calculate Kv(heat flux) according to Eq.1. 
Eq. (1)    𝐾𝑣 =
ℎ𝑒𝑎𝑡 𝑓𝑙𝑢𝑥
(𝑇𝑠−𝑇𝑝)
 
where heat flux [W/m2] and shelf temperature Ts [°C], are measured by the heat flux sensor and 
Tp [°C] is determined by TCs located in the vials on top of the sensor. It is important to note that 
Eq. (1) is only valid in the steady state phase of primary drying [30]. 
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Ten T-type copper-constantan TCs (0.01 mm diameter; accuracy within 1 °C; Omega 
Engineering, Newport, CT, USA) were placed into the vials standing on the heat flux sensor and 
were used to measure Tp. Ts was determined by an external TC for the 1st generation sensor 
and by a built-in TC for the 2nd generation sensor.  
V.3.5 PRODUCT TEMPERATURE ESTIMATION BY LYOPAT®  
For Tp estimation, Kv is needed as a user input (Kv,user). Therefore, Kv,user was determined in an 
identical pre-cycle according to Eq.(1) as the mean Kv over 20 h of steady state primary drying 
of the pre-cycle. Tp,est was obtained by  LyoPAT® according to Eq.(2).  
Based on the knowledge of Kv, Eq. (1) can be transformed into Eq. (2) in order to calculate an 
estimated product temperature (Tp,est).  
Eq. (2)     𝑇𝑝,𝑒𝑠𝑡 =
 𝐾𝑣∗𝑇𝑠−ℎ𝑒𝑎𝑡 𝑓𝑙𝑢𝑥 
𝐾𝑣
 
V.3.6 PERFORMANCE CHECK OF HEAT FLUX SENSORS 
For the one-vial performance checks, one 10R vial was filled with 9 ml of water at 0, 20, 30, 50, 70, 
and 90 °C was centrally placed on the sensor (shelf at room temperature 21 °C; not controlled). Ts 
(determined by heat flux sensor), Tp by TC and heat flux was recorded over five minutes (two data 
points per minute). This experiment was performed three times in order to investigate the sensor´s 
repeatability. 
To analyze the repeatability and linear measurement range, the obtained heat flux data was plotted 
against ΔT(Ts-Tp). According to Eq 1, the resulting slope provides Kv(heat flux).  
Additionally, the effect of moisture between shelf and vial was simulated, by dipping the vial into 
water to wet the outer surface of the vial bottom before it was placed on the center of the sensor. 
The heat flux results were compared to those obtained with a dry vial. Furthermore, a “rose” of 
seven 10R vials filled with 9 ml of ice water was shifted by 10 mm off center. The values generated 
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before and after the shift were compared. The effect of moisture was investigated on the 2nd 
generation sensor, whereas the impact of a vial shift on the sensor was evaluated on both sensors.  
For repeatability tests, the performance of the heat flux measurement under process conditions 
using a partially filled shelf and a fully filled shelf was examined (each setup three times) for the 
1st and the 2nd generation sensor. For both setups, the shelf was completely filled with vials in 
order to keep the vials in the correct position over the sensor. In case of the partially filled shelf, 
150 2R vials (1st generation sensor) or 65 10R vials (2nd generation sensor) were filled with 1 ml 
and 3 ml of a 5% sucrose solution. A fully filled shelf corresponds to 772 2R vials and 332 10R 
vials, which results in a ratio of 20% for the partially filled shelves. The 5% sucrose solution was 
subjected to the random nucleation freezing and the standard drying protocol (Table V-1).  
The applicability of heat flux measurements to (i) solutions of different solid content (5, 10, 20 
and 50% sucrose in water (w/v)) and (ii) filling volumes (1, 3 and 5 ml of 5% sucrose solution) 
was studied with the 2nd generation sensor (10R vials) using the controlled nucleation and 
standard drying protocol (Table V-1). 
V.3.7 SECONDARY DRYING KINETICS 
One freeze-dryer shelf loaded with (i) 332 10R vials (3 ml of 5% sucrose solution) or (ii) 400 6R 
vials (3 ml of 10 mg/ml BSA solution) was subjected to the controlled nucleation and standard 
drying protocol (Table V-1). At set time points during secondary drying, the chamber was 
backfilled with dry nitrogen. The freeze-dryer door was opened, and selected vials were 
manually stoppered under nitrogen flush. At each time point, three samples from front, back and 
center of the shelf were taken. Subsequently, the chamber vacuum was reconditioned, and 
secondary drying was continued. Throughout secondary drying, the heat flux was monitored 
(rear sensor) and compared to the sample`s residual moisture content determined by Karl 
Fischer titration. The vials on the sensor were not moved throughout the study. 
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V.3.8 RESIDUAL MOISTURE DETERMINATION BY KARL FISCHER 
Residual moisture of the freeze-dried product was determined by coulometric Karl Fischer 
titration with an Aqua 40.00 titrator (Analytik Jena, Jena, Germany) using a head-space module. 
Sample aliquots of approximately 20 mg were prepared in 2R vials (stoppered with rubber 
stoppers) under controlled residual humidity of less than 10% in a glove box. Blank values were 
obtained from empty vials treated identically. A system test was performed daily by measuring 
a pure water standard at 170 °C (Apura® water standard oven 1.0, Merck KGaA, Grafing, 
Munich). 
V.3.9 HEADSPACE MOISTURE MEASUREMENT BY FREQUENCY 
MODULATED SPECTROSCOPY (FMS) 
The partial pressure of water vapor in the vial headspace was measured using an FMS-1400 
(Lighthouse Instruments, Charlottesville, VA, USA). Before usage the system was purged with 
5 l/min nitrogen gas for at least 30 min to minimize background ambient moisture contribution 
to the signal. Prior to measurements, a two-point calibration followed by a five-point system 
suitability test was performed on a daily basis. The measurement time was set to 5 sec. 
Headspace moisture values are provided as the partial pressure of water vapor in mbar.  
Sample vials were allowed to equilibrate to room temperature before the head space 
measurement was performed. As the FMS is a non-destructive method, the same vials were 
used for FMS and Karl Fischer analysis. 
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V.4 RESULTS 
V.4.1 ONE-VIAL PERFORMANCE CHECK 
First, the performance of the sensors with respect to repeatability, linear measurement range of 
ΔT(Ts-Tp) and robustness was tested.  
To compare the repeatability of the 1st generation sensor with the 2nd generation sensor, the 
mean Kv(heat flux) over a 5 min measuring time and the corresponding relative (RSD) and 
absolute (STD) standard deviation were calculated. For the 1st generation sensor, a mean 
Kv(heat flux) of the three repeats of 33.4 W/m2*°C (RSD=8.1%; STD=2.7 W/m2*°C) was 
observed. The 2nd generation sensor showed improved repeatability with a measured Kv(heat 
flux) of 55.6 W/m2*°C (RSD=1.9%; STD=1.1 W/m2*°C). The difference in the measured Kv(heat 
flux) values of the two sensors can be attributed to the different sensor architecture (external 
thermocouple of the 1st generation sensor vs built-in thermocouple and additional scaffolding of 
the 2nd generation sensor), which contributes to an improved accuracy for the 2nd generation 
sensor.  
Next, the performance of the sensor over a temperature range from 0 °C to 90 °C was 
examined. Both sensors showed a linear correlation (R2=0.992) between the measured heat 
flux and ΔT(Ts-Tp) over the investigated temperature range (data not shown).  
In a further scenario, moisture was introduced between the shelf and the vial to address the 
robustness of the sensor. This experiment was performed with the 2nd generation sensor, as all 
previous results showed a clear advantage of the 2nd generation sensor. The measured heat 
flux towards the wet vials (1115.4 W/m2) was almost double the heat flux of the dry vials 
(638.7 W/m2). The inserted TCs did not indicate a difference in Tp between the wet and dry vial.  
Last, the robustness of heat flux measurements towards user influence was investigated. 
Therefore, it was simulated that the vials are not placed on the exact same spot but shifted by 
10 mm towards the edge of the sensor. For the 1st generation sensor a change in mean heat 
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flux by 122.9 W/m2 (717.1 W/m2 vs 594.2 W/m2) was detected. In contrast, for the 2nd generation 
sensor a change by only 6.8 W/m2 (638.7 W/m2 vs 631.9 W/m2) was recognized. 
V.4.2 PERFORMANCE CHECK UNDER PROCESS CONDITIONS 
The repeatability of the heat flux measurements between different freeze-drying runs of the 
same protocol under partial and full filling conditions was tested (Figure V-2).  
 
Figure V-2: Overlay of heat flux patterns of the 2nd generation sensor (n=3) during freeze-drying for fully loaded shelf (A) 
and partially loaded shelf (B). The repeatability of heat flux measurement was determined in three independent 
freeze-drying runs following the standard drying protocol after random nucleation. 
The heat flux data were reproducible between the multiple experiments (n=3) performed using 
both partially and fully filled shelves. The mean heat flux of the three repeats (over 6 h of steady 
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state primary drying) was 98.2 W/m2 (RSD=5.0%; STD=4.9 W/m2) for the partially filled shelf 
and 98.0 W/m2 (RSD=5.5%; STD=5.4 W/m2) for the fully filled shelf. 
The applicability of heat flux measurements for sucrose solutions of different concentrations and 
different vial filling volumes was tested, by comparing the mean heat flux and Kv(heat flux) value 
over 6 h of steady state primary drying (Figure V-3). A decrease in heat flux was observed with 
increasing sucrose concentration, as well as a linear correlation between the mean heat flux in 
steady state and the sucrose concentration (Figure V-3A). The mean Kv(heat flux) values of the 
5, 10 and 20% sucrose solution fluctuate around 11.7 W/m2*° (STD=0.9 W/m2*°C) whereas the 
Kv(heat flux) of the 50% sucrose solution was remarkably lower (8.5 W/m2*°C).  
 
Figure V-3: (A) Heat flux measurements for different sucrose concentrations (10R vials; 3 ml filling volume). For the 50% 
sucrose solution no steady state could be reached and Eq. 1 is not valid, which is indicated by the blue striped column. 
(B) Heat flux measurements for different filling volumes (10R vials; 1, 3, 5 ml filling volume) of a 5% sucrose solution. 
No change of the mean heat flux with increasing filling volumes was observed and a mean 
Kv(heat flux) of 11.9 W/m2*°C (STD=0.4 W/m2*°C) was measured (Figure V-3B).  
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V.4.3 MONITORING OF A FREEZE-DRYING PROCESS BY HEAT FLUX 
MEASUREMENTS 
V.4.3.1 MONITORING OF THE FREEZING STEP 
The heat flux was monitored during freezing by random and controlled nucleation of 10R vials 
with 3 ml of a 5% sucrose solution (Figure V-4A and 4B). Heat flux and Tp measured by TC 
decreased until nucleation occurred. For random nucleation, an irregular profile was observed 
by both heat flux and TC (Figure V-4A). For controlled nucleation, the heat flux and TC profile 
was more uniform in the moment of nucleation, as all vials on the sensor nucleated at the same 
time (Figure V-4B).  
 
Figure V-4: Freezing with random nucleation (A) and controlled nucleation (B) (showing one example of n=3) of a 5% 
sucrose solution (10R vials; 3 ml filling volume). 
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V.4.3.2 MONITORING OF PRIMARY DRYING 
The aim was to test the sensor´s ability to detect the end of primary drying compared to TC and 
comparative pressure measurement. Therefore, the heat flux data gained in the experiments 
shown in Figure V-3 were related to the corresponding Tp and comparative pressure 
measurement data at the time point, when heat flux reached zero. One example (5 % sucrose 
solution with a 3 ml filling volume in a 10R vial), is shown in Figure V-5.  
 
Figure V-5: Comparison of the end of primary drying determined via (A) thermocouples, (B) heat flux and (C) comparative 
pressure measurement of a 5% sucrose solution (10R vials; 3 ml filling volume). 
In all cases, the end of primary drying determined by heat flux measurements was in accordance 
with the endpoint detected by TC, while comparative pressure measurement still indicated a 
pressure difference. For the provided example ΔT was 0.26 °C, which is below the accuracy 
specification of +/- 1 °C of the used TC, when heat flux reached zero (Figure V-5). The difference 
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in endpoint assessment between comparative pressure measurement and TC reading or heat 
flux measurement was expected as comparative pressure measurement accounts for the last 
few vials, which finish primary drying. In this context it should be clarified that the end of primary 
drying determined with the used methods does not indicate completion of sublimation. For heat 
flux or TC measurements that means that the heat transferred by the shelf after completion of 
sublimation is used to heat the container. When the container reaches the shelf temperature, 
the heat transfer lacks the driving force and approaches zero. In the case of comparative 
pressure measurement, the pressure ratio becomes equal to one when there is no water vapor 
in the chamber. However, ice sublimation could have been completed before as the 
concentration of water vapor in the chamber, after sublimation was completed, is a 
consequence of the fluid dynamics of the water. Taking this into account, for all methods 
sublimation most likely is completed prior to the determined end of primary drying time. 
V.4.3.3 MONITORING OF SECONDARY DRYING 
To investigate the sensor´s ability to indicate the end of secondary drying the heat flux in the 
course of secondary drying was compared to the residual moisture of the product (Figure V-6). 
The heat flux curves for both 5% sucrose (Figure V-6A) and 10 mg/ml BSA formulation (Figure 
V-6B) showed a steep decrease during the first 4 to 5 h of secondary drying. After that, the heat 
flux levelled off at negative values of about -2 W/m2 for the 5% sucrose solution and at about -
5 W/m2 for 10 mg/ml BSA formulation. The residual moisture determined by Karl Fischer also 
showed a steep decrease in the initial phase of secondary drying followed by a plateau phase. 
Within the 5% sucrose solution experiment, the residual moisture decreased steeply from 2.3% 
to 0.8% in the first 6 h. In the next 8 h, the residual moisture changed only by 0.3%. For the 
10 mg/ml BSA formulation, Karl Fischer measurements detected a steep decrease from 2.9% 
to 1.0% in residual moisture within the first 10 h of secondary drying, before the second phase 
was reached.  
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Figure V-6: (A) Heat flux of 5% sucrose solution (10R vials; 3 ml filling volume) measured during secondary drying, 
compared to residual moisture determined by Karl Fischer. (B) Heat flux of 10 mg/ml BSA formulation (10R vials; 3 ml 
filling volume) measured during secondary drying, compared to residual moisture determined by Karl Fischer and head 
space moisture analysis. 
For the 10 mg/ml BSA formulation, additional headspace moisture measurements by FMS were 
performed. The partial pressure of water vapor in the vial head space, which corresponds to the 
headspace moisture decreased for the first 7 h of secondary drying before it reached a plateau 
at 0.15 mbar. Overall, it was not possible to reliably monitor the end of secondary drying by heat 
flux measurements, as the residual moisture still declined whereas heat flux has already 
reached a minimum level.   
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V.4.4 PRODUCT TEMPERATURE ESTIMATION BY LYOPAT  
The aim of this experiment was to compare Tp,est (based on Kv,user) with the product temperature 
determined by thermocouples (Tp(TC)). From the beginning until approximately 25 h of primary 
drying, Tp,est and Tp(TC) are in good accordance (Figure V-7). Afterwards, Tp(TC) showed a 
steeper increase than Tp,est. The end of primary drying was indicated by both methods at 40.5 h. 
 
Figure V-7: Noninvasive Tp monitoring during primary drying based on heat flux measurements in comparison to Tp 
monitoring by TC readings of a 5% sucrose solution (10R vials; 3 ml filling volume).  
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V.5 DISCUSSION 
V.5.1 ONE-VIAL PERFORMANCE CHECK 
The one-vial performance check showed that for accurate and repeatable heat flux 
measurements a flat placement of the vials on and across the sensor´s edges is crucial (Figure 
V-1A). The scaffold around the actual 2nd generation sensor provided the necessary even stand 
for the vials to assure repeatable and accurate heat flux measurements.  
Further, moisture between the sensor and the vials was found to strongly impact heat flux 
measurements, because the higher thermal conductivity of water, compared with air, results in 
higher heat flux values. Tp by TC is not affected by moisture between shelf and vial. 
Nevertheless, the moisture effect on heat flux measurements should be kept in mind when 
applied e.g. for freeze-drying cycles with loading on pre-cooled shelves, as the water 
condensing on the shelf during loading may lead to a higher heat flux value. However, under 
typical process conditions, the condensed water will have been sublimed by the time the 
process reaches the steady state of primary drying and the Kv determination would also be 
accurate in this case. During the performance check, we experienced that the mounting of the 
sensor was robust against manual cleaning with 70% isopropanol and water. Careful loading of 
vials to the shelf is required as the sharp borders of the tray could loosen the sensor. 
Robustness towards sterilization (e.g. steam or H2O2) was not investigated in this study. In 
addition, both sensors were able to measure the heat flux reliably and linearly over a range of 
ΔT from 20 to-50 °C, which is relevant for pharmaceutical freeze-drying processes.   
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V.5.2 PERFORMANCE CHECK UNDER PROCESS CONDITIONS 
The 2nd generation sensor measured the heat flux repeatable and independent of the shelf filling 
degree. This is important as it enables process development with partially filled shelves, which, 
in turn, may reduce material and time.  
During the application of heat flux measurements to different product concentrations, the sensor 
showed the expected decrease in heat flux as the higher product resistance (Rp) at higher 
product concentrations (i.e. higher solids content) leads to lower sublimation rates and therefore 
lower heat flux values [32]. The corresponding Kv values for the 5%, 10% and 20% sucrose 
solution were independent of the sucrose concentration and stayed constant during the pseudo-
steady state of primary drying. The Kv value obtained for the 50% sucrose solution was 
remarkably lower. It can be assumed that this extremely high solids content caused a very low 
sublimation rate. Therefore, the heat supplied by the shelf and the heat needed for sublimation 
was not in balance, which results in a warming of the product. Consequently, no pseudo-steady 
state was reached, and Eq. 1 was not valid, which resulted in the deviation of the Kv value. An 
error in heat flux measurement could be excluded as the heat flux measured for the 50% 
sucrose solution met the linear correlation between measured heat flux and product 
concentration. Within the application of the sensor to different filling volumes, heat flux 
measurements also showed reliable results. Generally, a decrease in heat flux with increasing 
filling volume is expected, as the dry layer thickness directly correlates with the Rp [33]. As we 
compared the means over the first 6 h of primary drying, we assumed that no difference 
between the filling volumes will be obvious at this early stage of primary drying, which was 
confirmed by the experimental data (no statistically relevant difference) (Figure V-3B). 
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V.5.3 MONITORING OF A FREEZE-DRYING CYCLE BY HEAT FLUX 
MEASUREMENTS 
The ability to detect the nucleation event of individual vials during the freezing step was 
comparable between heat flux measurements and TCs. Heat flux measurements provide further 
insights into freezing kinetics. At the moment of nucleation, the sensor showed an interrupted 
steep decrease in heat flux (Figure V-4). In the following phase of crystal growth and 
solidification, no information is provided by TCs, whereas heat flux measurements indicate the 
end of ice crystallization based on the end of latent heat production by a change in heat flux 
direction. The lack of the latent heat production causes the product temperature to approach 
the cooler shelf temperature, thus ΔT(Ts-Tp) decreases and finally, heat flux reaches 0, which 
determines the end of freezing. The heat flux progress of controlled nucleated samples differed 
markedly from the pattern of random nucleated samples. From the irregular pattern of the 
random nucleated samples, it could be concluded that the vials showed heterogeneous freezing 
kinetics. In contrast, with controlled nucleation all vials in contact with the sensor followed the 
same freezing kinetics. From the difference in pattern, one can also distinguish between 
controlled nucleation and random nucleation during freezing, additionally to the thermal 
information the sensor provides. Recent work of Wang et al. has shown that primary (ice 
nucleation) and secondary (water and solute) crystallization of a 5% NaCl solution was 
successfully detected by heat flux measurements [34]. 
In primary drying, the focus was to compare the sensor´s ability to detect the end of primary 
drying with TCs or comparative pressure measurement, respectively. The heat flux sensor data 
agreed with those obtained using TCs. With respect to batch representation, some 
consideration should be taken into account. For progress into the secondary drying step, it is 
critical that primary drying has finished for all vials. As the sensor monitors only a few vials, it is 
crucial to mount the sensor on the coldest spot of the freeze-dryer shelf, where the vials dry 
slowest. This is comparable to TCs. However, the sensor is non-invasive and therefore no 
influence of the sensor on freezing needs to be suspected. It would be recommended to use 
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more than one sensor to also monitor the warmest spot of the shelf to assure that Tc is not 
exceeded. Further, a larger sensor could help to improve batch representation of the endpoint 
detection. Comparative pressure measurement was found to still provide one of the easiest and 
safest method for a batch representative detection of the endpoint of primary drying. However, 
it lacks the ability to monitor the product temperature. In conclusion, heat flux measurements 
are a valuable tool to determine an average endpoint of primary drying, however, techniques 
that include the last few vials, such as comparative pressure measurement, should be preferred 
for monitoring the end of primary dying that drives the decision to progress into secondary 
drying.  
During secondary drying, heat flux measurements could not detect the small amount of 
desorption heat and could not indicate the progress of drying as for example by monitoring the 
residual moisture content. The heat flux already levelled off, whereas the residual moisture 
determined by Karl Fischer or via headspace moisture further decreased (Figure V-6). 
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V.5.4 PRODUCT TEMPERATURE ESTIMATION  
The possibility to directly measure the heat flux and thus Kv and from this calculate Tp,est, clearly 
distinguishes heat flux measurements from a simple temperature monitoring tool. To estimate 
the product temperature, Kv needs to be determined in a pre-cycle during the pseudo-steady 
state of primary drying (no need to fully complete the pre-cycle) using TCs to measure Tp. In 
this work, an overall good accordance between Tp,est and Tp by TC was shown (Figure V-7). 
Towards the end of primary drying, a minor deviation between product temperatures determined 
by the different approaches was observed. This might be caused by several reasons. On the 
one hand, it is not possible to place a TC in the way that it has contact to the ice until the very 
last moment. The TC will lose the contact at some point, which results in an increase of the 
measured Tp. On the other hand, the Kv,user is kept constant throughout the process to calculate 
Tp,est. However, it is known that the correlation between Kv and heat flux is only valid during 
pseudo-steady state (Eq.1). Towards the end of primary drying the pseudo-steady state is no 
longer given. Therefore, Kv would change, which is not considered in Tp,est as the Kv,user is pre-
set for this experiment. With ΔT(Ts-Tp) approaching zero, the difference between Tp, est and 
Tp(TC) levels off. The accuracy of the Kv determination by heat flux measurements was not 
investigated in this study. In previous work, the authors showed that due to the sensor´s position 
below the vials, the sensor does not detect all of the heat from radiation [31]. Further studies 
are ongoing to investigate these phenomena. 
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V.6 CONCLUSION 
Our systematic evaluation proofed that heat flux measurements are a reliable and promising 
new tool suitable for freeze-drying process monitoring. Heat flux measurement is a non-invasive 
alternative to TCs, for monitoring selected vials. With the current set-up, the technique is not 
able to monitor a whole batch. As the sensors can be mounted tightly on the shelf, no manual 
handling is required that offers the potential for an application in production. The application of 
heat flux measurements is suitable for container systems that are in direct contact with the 
sensor surface, e.g. vials. One limitation is the usage of the technique for monitoring of 
secondary drying, because the small amount of desorption heat is below the limit of detection 
of the sensor. Overall, the direct measurement of the transferred heat, compared to the simple 
temperature measurement of thermocouples, enables to gain more insights in the freezing 
process and renews process development by using energy transfer as a control parameter.  
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The goal of product development is, besides developing a stable formulation, to establish robust 
manufacturing processes to consistently produce high quality products. With the FDA`s cGMP 
initiative and the introduction of QbD, researchers focused on a thorough process 
understanding and control. This also includes the development of PAT tools to ensure process 
monitoring during production or to improve process understanding. In this context, two 
innovative technologies, controlled nucleation and heat flux measurement, gained interest in 
the field of freeze-drying. The aim of this thesis was to evaluate, in case of controlled nucleation, 
its potential to improve product quality, process control, and efficiency, and in case of heat flux 
measurements, its potential as a new PAT tool.  
A general introduction into the principles of QbD and the investigated techniques, CN and heat 
flux measurements is provided in Chapter I. 
The objective of Chapter II was to evaluate the combination of controlled nucleation with 
aggressive primary drying for highly concentrated protein formulations and the effect of this 
combination on product properties. By this combination, CN and an aggressive lyo cycle PD 
time was drastically reduced, independent of the application of CN. Product characteristics, 
such as cake appearance, morphology, pore size, SSA and RM were comparable between 
conservative and aggressive PD lyo cycles. Furthermore, the positive effect of CN on 
reconstitution time reduction was detected after conservative and aggressive PD lyo cycles. 
Thus, this positive effect of CN on reconstitution time is a robust observation and does not 
depend on the drying protocol.  
In Chapter III, the main objective of this thesis, the potential of CN for improving other product 
quality attributes, such as the physico-chemical stability of protein therapeutics, was evaluated. 
The performed stability studies exhibited that CN did neither have a positive nor a negative 
effect on mAb stability compared to RN. Besides that, it was observed that the applied CN 
protocol and not only TN determined the SSA of the final product. Furthermore, it was 
demonstrated that polysorbate promotes the crystallization of sucrose in lyophilized products 
stored at elevated temperatures.  
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In Chapter IV, two key challenges for the practical application of CN were addressed: First, how 
to monitor if CN was successfully performed in all vials of a batch and second, if it is necessary 
to apply the same CN method in development and production scale. Additionally, based on the 
conclusions of Chapter III, impact factors, such as nucleation protocol, TN, formulation 
composition or protein concentration, on the SSA of the final product were assessed. Regarding 
the first challenge, frequency modulated spectroscopy (FMS) was successfully evaluated as a 
monitoring tool to non-destructively measure nucleation success on a high-throughput basis. As 
FMS enables to determine the partial pressure of water vapor as a surrogate for residual 
moisture, the measured data was used to assess inter-vial batch homogeneity during 
freeze-drying (the freeze-drying process was stopped shortly after primary drying) and of the 
final product. Hereby, an improved inter-vial batch homogeneity after primary drying for CN 
samples was detected, but these advantages in homogeneity were no longer present in the final 
product. The fact that CN improved batch homogeneity during primary drying supports the 
hypothesis that CN could facilitate scale-up, however, this was not investigated within this work 
and has not yet been studied. In context of the question, if it is necessary to apply the same CN 
method within the different scales, it was shown that three ice fog CN methods, VERISEQ® 
system, FreezeBooster® and Geidobler et al., resulted in similar product quality attributes with 
only minor differences in RM of the lyophilized product. In conclusion, applying different ice fog 
CN methods in development and production scale would most likely not change the product 
properties much. Finally, the observations of Chapter III that TN is not the only determining factor 
for ice morphology (and consequently SSA) were confirmed. Besides TN, the fact whether a CN 
method or a random freezing protocol was applied and the used formulation (sugar) impacted 
the SSA. Consequently, for practical application, it should be considered that a higher TN does 
not necessarily lead to additional primary drying time reduction but poses a higher risk for not-
controlled nucleated products compared to a TN that safely assures 100% controlled nucleation 
of the product vials.  
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Chapter V represents the second part of this thesis and provides the evaluation of heat flux 
measurements as a new PAT tool to improve monitoring and process understanding of 
freeze-drying cycles. Compared to state-of-the art thermocouples, heat flux measurements are 
non-invasive and easier in handling. Furthermore, they provide additional information, which 
can be used to calculate critical process parameters. However, heat flux measurements are not 
a batch representative technique and the fact that they are only suitable for container systems 
being in direct contact with the sensor surface, e.g. vials, poses a limitation. Moreover, the 
technique was not suitable for monitoring secondary drying, because the small amount of 
desorption heat is below the limit of detection of the sensor. Overall, the direct measurement of 
the transferred heat improves process development by using energy transfer as a control 
parameter. From the study presented in Chapter V, it was concluded that heat flux 
measurements are a reliable and promising monitoring tool for freeze-drying processes. 
When putting the findings of this thesis into the context of QbD, CN could not enhance QbD 
approaches for freeze-drying in all aspects. The principles of QbD comprise the improvement 
of product quality or assurance of product quality by controlled and robust processes. This thesis 
showed that CN did not directly improve product quality with respect to mAb stability or inter-vial 
batch homogeneity of the final product. Solely, for special products, it was shown to shorten 
reconstitution times. However, the improved inter-vial batch homogeneity during primary drying 
and the robustness of the techniques, shown by the fact that different ice fog CN methods 
resulted in comparable product quality attributes, could supports CN`s suitability for the QbD 
concept.  
Additionally, heat flux measurements, which were shown to be a valuable PAT tool, could 
support QbD approaches for freeze-drying. Besides monitoring of critical endpoints, e.g. 
freezing or primary drying, heat flux measurements provide critical process parameters. The 
creation of a design space for a freeze-drying product by the application of heat flux 
measurements would be of great interest to further integrate the cGMP initiative into freeze-
dried products and thus, should be investigated further. Overall, it should be considered that the 
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complexity of the freeze-drying process reveals that a single tool would not be able to control 
and monitor all aspects of this multi-step process. By combining e.g. CN with heat flux 
measurements and thermocouple readings, or TDLAS, it would be possible to develop, control 
and transfer robust freeze-drying processes that assure product quality at every stage of 
development.  
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VII.1 LIST OF ABBREVIATIONS 
BET Brunauer, Emmett and Teller Theory 
BRT Barometric temperature measurement 
BSA Bovine serum albumin 
BTM Barometric temperature measurement 
CMC Critical micelle concentration 
CN Controlled nucleation 
DLS Dynamic light scattering 
DPE Dynamic parameters estimation 
DSC Differential scanning calorimetry 
FDM Freeze-drying microscopy 
FMS Frequency modulated spectroscopy 
HMW High(er) molecular weight species 
HP-SEC High performance size exclusion chromatography 
KF Karl Fischer titration 
Kv vial heat transfer coefficient 
Kv,user vial heat transfer coefficient as user input 
LC Lyo cycle 
LDH Lactate dehydrogenase 
mAb Monoclonal antibody 
MFI Micro-Flow Imaging 
MS Mass spectrometry 
MTM Manometric temperature measurement 
OFS Optical fiber system 
PAT Process analytical technology 
pc Chamber pressure 
PD Primary drying 
PDI Polydispersity index 
PES Polyethersulfone membrane 
PRA Pressure rise analysis 
PRT Pressure rise test 
PS Polysorbate 
PVDF Polyvinylidenfluorid membrane 
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R2 Correlation coefficient 
RM Residual moisture 
RN Random nucleation 
Rp Product resistance 
RSD Relative standard deviation 
RTD Resistance temperature detectors 
SDS Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SD Secondary drying 
SEM Scanning electron microscopy 
SSA Specific surface area 
STD Standard deviation 
TC Thermocouples 
TDLAS Tunable diode laser absorption spectroscopy 
TFF Tangential flow filtration 
Tg Glass transition temperature of the lyophilized product 
Tg` Glass transition temperature of the frozen product 
TN (Ice) nucleation temperature 
Tp Product temperature 
Tp,est Estimated product temperature 
Ts Shelf temperature 
XRD X-ray powder diffraction 
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VIII.1 SUPPLEMENTARY MATERIAL FOR CHAPTER II 
 
Figure VIII-1: Tc and Tg` values of the different BSA concentrations. Extrapolated Tg` values for 150 mg/ml and 200 mg/ml 
BSA are indicated by open circles.  
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Figure VIII-2: Examples of photographs of BSA and mAb lyophilizates processed by different lyo cycles.  
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VIII.2 SUPPLEMENTARY MATERIAL FOR CHAPTER III 
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Figure VIII-3: Photographs of mAb1 and mAb2 lyophilizates taken at all time points of the high concentration study 
(storage at 40 °C/75% r.H.).  
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Figure VIII-4: Tg over storage time for (A) mAb1 and (B) mAb2 of the high concentration study. 
 
 
Figure VIII-5: Overlay of XRD-refractograms of mAb1 CN and mAb1 RN samples at all timepoints. 
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Figure VIII-6: Size distribution based on intensity detection of the high concentration study. (A) mAb1 CN, (B) mAb1 RN, 
(C) mAb2 CN and (D) mAb2 RN.  
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Figure VIII-7: Photographs of mab1 and mab2 lyophilizates taken at all time points of the low concentration study (storage 
at 40 °C/75% r.H.). 
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Figure VIII-8: Tg over storage time for (A) mAb1 and (B) mAb2 of the low concentration study. 
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1 2 3 4 5 6 7 8 9 10 No. Sample name 
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4 T3m_CN 
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10 MW Marker 
Figure VIII-9: SDS-page under non-reducing conditions of mAb2 T3m and T7m samples.  
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Figure VIII-10: SDS-page under reducing conditions of mAb2 T3m and T7m samples. 
460 kDa 
 
268 kDa 
 
238 kDa 
 
171 kDa 
 117 kDa 
 
71 kDa 
 55 kDa 
 44 kDa 
 31 kDa 
 
200 kDa 
 116.3 kDa 
 
97.4 
kDa 
 
66.3 
kDa 
 
55.4 
kDa 
 
36.5 
kDa 
 
31 k a 
 
21.5 
kDa 
 
14.4 
kDa 
 6 kDa 
 2.5 kDa 
 
3.5 kDa 
 
CHAPTER VIII 
160 
 
Figure VIII-11: z-average of CN and RN samples of (A) mAb1 and (B) mAb2 low concentration study over storage time. 
 
 
Figure VIII-12: Cumulative particle counts of particles larger 1 µm for (A) mAb1 low concentration and (B) mAb2 low 
concentration over storage time.  
 
APPENDIX 
161 
 
Figure VIII-13: Freeze-drying process documentation: Shelf setpoint, product temperature and pressure traces over 
process duration. (A) mAb1 high concentration study CN and RN process. (B) mAb2 high concentration study CN and RN 
process. 
 
Figure VIII-14: Shelf temperature setpoint, product temperature and chamber pressure traces of low concentration study 
CN and RN process for (A) mAb1 and (B) mAb2.  
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Table VIII-1: Overview of primary drying duration in hours of all studies and processes. The time when the shelf 
temperature reached the set primary drying temperature until the thermocouples indicated the end of primary drying, was 
considered as primary drying duration. 
Duration primary drying in [h] 
Study 
CN-5 
-PS 
CN-5 
+PS 
CN-10 
-PS 
CN-10 
+PS 
RN 
-PS 
RN 
+PS 
mAb1 
high conc 
6.8 --- --- --- 9.4 --- 
mAb2 
high conc 
--- 10.0 --- --- --- 11.7 
mAb1 
low conc 
61.8 59.1 66.0 77.7 61.5 65.9 
mAb2 
low conc 
52.7 53.5 --- --- 60.4 65.7 
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VIII.3 SUPPLEMENTARY MATERIAL FOR CHAPTER IV 
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Figure VIII-15: Optical evaluation of all freeze-drying runs of the sucrose formulation 
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Figure VIII-16: Optical evaluation of all freeze-drying runs of the trehalose formulation. 
